var title_f43_32_44544="Uvular edema caustic ingestion";
var content_f43_32_44544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uvular edema and tongue burns from caustic ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44544=[""].join("\n");
var outline_f43_32_44544=null;
var title_f43_32_44545="Pediculosis humanus humanus";
var content_f43_32_44545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pediculosis humanus humanus (human body louse)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo provided by B. Thomas Photo Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44545=[""].join("\n");
var outline_f43_32_44545=null;
var title_f43_32_44546="Anatomy male genitalia";
var content_f43_32_44546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74328&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Anatomy of the male genitalia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Girardin, BW, Faugno, DK, Seneski, PC, et al. Color Atlas of Sexual Assault. Mosby-Year Book, Inc. 1997:12. Copyright &copy; 1997 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44546=[""].join("\n");
var outline_f43_32_44546=null;
var title_f43_32_44547="Coarctation aorta PA";
var content_f43_32_44547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70656%7ECARD%2F79548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70656%7ECARD%2F79548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain radiograph showing coarctation of the aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain frontal chest radiograph from a patient with known coarctation of the aorta demonstrates an absence of the proximal descending aortic arch shadow in the expected location (arrow), immediately superior to the left main pulmonary artery. Another plain radiographic finding, not seen in this example, includes notching of the posterior thoracic ribs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortogram showing coarctation of the aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aortogram, obtained after injection of contrast material into the root of the aorta in a patient with coarctation of the aorta, demonstrates marked focal narrowing of the proximal descending thoracic aorta (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44547=[""].join("\n");
var outline_f43_32_44547=null;
var title_f43_32_44548="CT scan of internal hernia after gastric bypass";
var content_f43_32_44548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography (CT) scan of internal hernia after gastric bypass (mesenteric swirl sign)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrow points to a classic swirl sign of vessels with obstructed and collapsed bowel after gastric bypass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44548=[""].join("\n");
var outline_f43_32_44548=null;
var title_f43_32_44549="Fludrocortisone: Pediatric drug information";
var content_f43_32_44549=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fludrocortisone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"    see \"Fludrocortisone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/11/38069?source=see_link\">",
"    see \"Fludrocortisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Florinef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Mineralocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12674640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Congenital adrenal hyperplasia (salt losers): Maintenance: 0.05-0.2 mg/day in 1-2 divided doses (AAP, 2010; Speiser, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"      see \"Fludrocortisone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: 0.05-0.1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Congenital adrenal hyperplasia (salt losers): Maintenance: 0.05-0.3 mg/day (AAP, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 0.05-0.2 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 0.1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Addison's disease; partial replacement therapy for adrenal insufficiency; treatment of salt-losing forms of congenital adrenogenital syndrome; has been used in conjunction with an increased sodium intake for the treatment of idiopathic orthostatic hypotension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Florinef&reg; may be confused with Fioricet&reg;, Fiorinal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F171985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac enlargement, CHF, edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Delirium, depression, emotional instability, euphoria, hallucinations, headache, insomnia, intracranial pressure increased, malaise, mood swings, nervousness, personality changes, pseudotumor cerebri, psychiatric disorders, psychoses, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, bruising, erythema, hirsutism, hives, hyperpigmentation, maculopapular rash, petechiae, purpura, rash, skin test reaction impaired, striae, subcutaneous fat atrophy, thin fragile skin, urticaria, wound healing (impaired)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cushing&rsquo;s syndrome, diabetes mellitus, glucose intolerance, growth suppression,  hyperglycemia, hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary-adrenal axis suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, esophagitis ulceration, pancreatitis, peptic ulcer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fractures, necrosis (femoral and humeral heads), muscle mass loss, muscle weakness, myopathy, osteoporosis, vertebral compression fractures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmos, glaucoma, increased intraocular pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (generalized), diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fludrocortisone or any component; CHF, systemic fungal infections",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be tapered gradually if therapy is discontinued; use with caution in patients with hypertension, edema, or renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of mineralocorticoids/corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, and phosphorus, and decreased sodium; with fludrocortisone a decrease in dietary sodium is often not required as the increased retention of sodium is usually the desired therapeutic effect",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6472611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with fludrocortisone; adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Monitor for hypoadrenalism in infants exposed to fludrocortisone during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes and glucose, blood pressure, serum renin",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent mineralocorticoid with glucocorticoid activity; promotes increased reabsorption of sodium and loss of potassium from distal tubules",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 42%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma: &sim;3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Biological: 18-36 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/11/38069?source=see_link\">",
"      see \"Fludrocortisone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if dizziness, severe or continuing headache, swelling of feet or lower legs, or unusual weight gain occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with salt-losing forms of congenital adrenogenital syndrome, use along with cortisone or hydrocortisone; fludrocortisone 0.1 mg has sodium retention activity equal to DOCA&reg; 1 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"Statement of Endorsement-Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(5):151. Available at file://pediatrics.aappublications.org/content/126/5/1051.extract. Accessed May 10, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics, &ldquo;Technical Report: Congenital Adrenal Hyperplasia,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(6):1511-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44549/abstract-text/11099616/pubmed\" id=\"11099616\" target=\"_blank\">",
"        11099616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Speiser PW, Azziz R, Baskin LS, et al, \"Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(9):4133-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44549/abstract-text/20823466/pubmed\" id=\"20823466\" target=\"_blank\">",
"        20823466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13306 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-9E6425AB09-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44549=[""].join("\n");
var outline_f43_32_44549=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171956\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052787\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12674640\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052781\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171935\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171921\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052791\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052790\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171987\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171985\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052795\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052780\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299344\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171930\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052798\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171931\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6472611\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052786\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052779\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052793\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052794\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052785\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052796\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13306\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13306|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=related_link\">",
"      Fludrocortisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/11/38069?source=related_link\">",
"      Fludrocortisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_32_44550="Protriptyline: Pediatric drug information";
var content_f43_32_44550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Protriptyline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?10/5/10327?source=see_link\">",
"    see \"Protriptyline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/60/39876?source=see_link\">",
"    see \"Protriptyline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vivactil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1033581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic (Secondary Amine)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1033610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/5/10327?source=see_link\">",
"      see \"Protriptyline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"     <b>",
"      Note:",
"     </b>",
"     Safe and effective use in children has not been established; controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents (Dopheide, 2006; Wagner, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents: Manufacturer labeling: Initial: 5 mg/dose given 2-3 times/day; may increase in 2 weeks as tolerated; slow titration is recommended in order to facilitate monitoring for adverse effects such as behavioral activation; usual dose: 15-20 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 10 mg/dose given twice daily; may increase every week as tolerated to a goal of 30-60 mg/day in 3-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivactil&reg;: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089820.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089820.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5033003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1033582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4425704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vivactil&reg; may be confused with Vyvanse&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, heart block, hyper-/hypotension, MI, palpitation, stroke, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delirium, delusions, dizziness, drowsiness, EPS, exacerbation of psychosis, fatigue, hallucinations, headache, hypomania, incoordination, insomnia, nightmares, panic, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, petechiae, photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement, galactorrhea, gynecomastia, increased or decreased libido, syndrome of inappropriate ADH secretion (SIADH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, decreased lower esophageal sphincter tone may cause GE reflux, diarrhea, heartburn, increased appetite, nausea, trouble with gums, unpleasant taste, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, impotence, testicular edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, leukopenia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, increased liver enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fine muscle tremor, numbness, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, eye pain, increased intraocular pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, excessive diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1033585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to protriptyline (cross-reactivity to other cyclic antidepressants may occur) or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur); concurrent use of cisapride; use in a patient during the acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4104406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause sedation; more common in adults than adolescents; sedation may result in impaired performance of tasks requiring alertness (eg, operating machinery or driving). Sedative effects may be additive with other CNS depressants and/or ethanol. The degree of sedation is low relative to other antidepressants. May aggravate aggressive behavior; more prevalent in adolescents compared to adults. May increase the risks associated with electroconvulsive therapy; limit such treatment to patients in whom it is essential. Consider discontinuing, when possible, prior to elective surgery. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods. May alter glucose regulation; both an increase and decrease in blood glucose has been reported; use with caution in patients with diabetes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause tachycardia and orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of hypotension or in patients where transient tachycardia and hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). The degree of anticholinergic blockade produced by this agent is moderate relative to other cyclic antidepressants; however, caution should still be used in patients with urinary retention, benign prostatic hyperplasia, narrow-angle glaucoma, increased IOP, xerostomia, visual problems, constipation, or history of bowel obstruction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities). The risk of conduction abnormalities with this agent is moderate-high relative to other antidepressants. Use caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage, alcoholism, or concurrent therapy with other drugs which lower the seizure threshold. Use with caution in hyperthyroid patients or those receiving thyroid supplementation (cardiac arrhythmias may occur). Use with caution in patients with hepatic or renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1033586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did not show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not discontinue abruptly in patients receiving high doses chronically (withdrawal symptoms may occur). To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). May worsen psychosis in some patients.  Protriptyline is not FDA approved for the treatment of bipolar depression.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F215281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protriptyline may enhance the arrhythmogenic effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1033599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Grapefruit juice may inhibit the metabolism of some TCAs and clinical toxicity may result.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5033004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, mental status, weight. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1033603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 70-250 ng/mL (SI: 266-950 nmol/L); Toxic: &gt;500 ng/mL (SI: &gt;1900 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1033601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibition of their reuptake by the presynaptic neuronal membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4104407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Onset of action: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Maximum effect: 4-12 weeks",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Duration: 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1033604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via N-oxidation, hydroxylation, and glucuronidation; first-pass effect (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 54-92 hours (average: 74 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 24-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1033619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/60/39876?source=see_link\">",
"      see \"Protriptyline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of protriptyline. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you feel more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol, grapefruit juice, and the herbal medicine St John's wort; limit caffeine intake. This medication may cause drowsiness, lightheadedness, impaired coordination, dizziness, or blurred vision and impair ability to perform activities requiring mental alertness or physical coordination. May cause dry mouth. Do not discontinue abruptly (withdrawal symptoms may occur). May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not take any new medication during therapy unless approved by prescriber. Take exactly as directed; do not increase dose or frequency; may take 2-3 weeks to achieve desired results. Maintain adequate hydration unless instructed to restrict fluid intake. May cause nausea, vomiting, loss of appetite, or disturbed taste (small frequent meals, good mouth care, chewing gum, or sucking lozenges may help); constipation; urinary retention (void before taking medication); postural hypotension (use caution climbing stairs or when changing position from lying or sitting to standing). Report chest pain, palpitations, or rapid heartbeat; muscle cramping, weakness, tremors, or rigidity; blurred vision or eye pain; breast enlargement or swelling; or yellowing of skin or eyes.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J  Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JR, &ldquo;Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1970, 49(8):1596-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/5431666/pubmed\" id=\"5431666\" target=\"_blank\">",
"        5431666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/3925584 /pubmed\" id=\"3925584 \" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith IE and Quinnell TG, \"Pharmacotherapies for Obstructive Sleep Apnoea: Where Are We Now?\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(13):1385-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/15212557/pubmed\" id=\"15212557\" target=\"_blank\">",
"        15212557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/5636628/pubmed\" id=\"5636628\" target=\"_blank\">",
"        5636628",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44550/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13062 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44550=[""].join("\n");
var outline_f43_32_44550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709377\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215269\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033581\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033610\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215248\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215233\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874824\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5033003\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033582\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425704\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215290\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033585\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4104406\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033586\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215281\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215242\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033599\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447521\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5033004\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033603\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033601\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4104407\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033604\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1033619\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13062\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13062|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/5/10327?source=related_link\">",
"      Protriptyline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/60/39876?source=related_link\">",
"      Protriptyline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_32_44551="Doxepin (systemic): Drug information";
var content_f43_32_44551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxepin (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/8/40069?source=see_link\">",
"    see \"Doxepin (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/59/24503?source=see_link\">",
"    see \"Doxepin (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8082208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10570484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Silenor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Doxepin&reg;;",
"     </li>",
"     <li>",
"      Doxepine;",
"     </li>",
"     <li>",
"      Novo-Doxepin;",
"     </li>",
"     <li>",
"      Silenor&reg;;",
"     </li>",
"     <li>",
"      Sinequan&reg;;",
"     </li>",
"     <li>",
"      Zonalon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8082558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Tertiary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8082233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression and/or anxiety:",
"     </b>",
"     Oral: Initial: 25-150 mg/day at bedtime or in 2-3 divided doses; may gradually increase up to 300 mg/day; single dose should not exceed 150 mg; select patients may respond to 25-50 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Insomnia (Silenor&reg;):",
"     </b>",
"     Oral: 3-6 mg once daily 30 minutes prior to bedtime; maximum dose: 6 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8082234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression and/or anxiety:",
"     </b>",
"     Oral: Initial: 10-25 mg at bedtime; increase by 10-25 mg every 3 days for inpatients and weekly for outpatients if tolerated. Rarely does the maximum dose required exceed 75 mg/day; a single bedtime dose is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: 3 mg once daily 30 minutes prior to bedtime; increase to 6 mg once daily if clinically needed",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15804890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8082235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use a lower dose and adjust gradually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silenor&reg;: Initial: 3 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]: 10 mg/mL (118 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silenor&reg;: 3 mg, 6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8082214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Silenor&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM206668.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM206668.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Antidepressant medications:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089129.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089129.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8082237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Oral: Do not mix oral concentrate with carbonated beverages (physically incompatible).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Silenor&reg;: Administer within 30 minutes prior to bedtime; do not take within 3 hours of food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8082265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Depression; treatment of insomnia (with difficulty of sleep maintenance)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8082267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic for certain chronic and neuropathic pain; anxiety",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxepin may be confused with digoxin, doxapram, doxazosin, Doxidan&reg;, doxycycline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SINEquan&reg; may be confused with saquinavir, SEROquel&reg;, Singulair&reg;, Zonegran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal [Finland] may be confused with Doxil brand name for doxorubicin (liposomal) [U.S.,  Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal brand name for doxepin [Finland] but also brand name for pyridoxine/thiamine [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8082276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Actual frequency may be dependent on diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hypertension (&lt;3%), hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, chills, confusion, disorientation, dizziness, drowsiness, fatigue, hallucinations, headache, seizure, somnolence/sedation (6% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, photosensitivity, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Blood sugar increased/decreased, breast enlargement, galactorrhea, gynecomastia, libido increased/decreased, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, aphthous stomatitis, constipation, diarrhea, gastroenteritis (&le;2%), indigestion, nausea (2%), trouble with gums, unpleasant taste, vomiting, weight gain, xerostomia; lower esophageal sphincter tone decrease may cause GE reflux",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Testicular edema, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, leukopenia, purpura, thrombocytopenia, purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Extrapyramidal symptoms, numbness, paresthesia, tardive dyskinesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, nasopharyngitis/upper respiratory tract infection (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, diaphoresis (excessive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, anemia, arthralgia, atrioventricular block, back pain, blepharospasm, chest pain, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), diplopia, dyspepsia, gingival recession, hematochezia, hyperbilirubinemia, hypermagnesemia, hypersensitivity, hypoacusis, infection, lacrimation decreased, lip blister, motion sickness, myalgia, palpitations, peripheral edema, tympanic membrane perforation, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8082272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxepin, drugs from similar chemical class, or any component of the formulation; narrow-angle glaucoma; urinary retention; use of MAO inhibitors within 14 days",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8082273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Doxepin is approved for treatment of depression in adolescents.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risk of suicidal behavior may be increased regardless of doxepin dose; antidepressant doses of doxepin are 10- to 100-fold higher than doses for insomnia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is very high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted; amnesia may also occur. Discontinue treatment in patients who report any sleep-related episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; higher doxepin concentrations may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Doxepin is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory compromise or sleep apnea; use is generally not recommended in patients with severe sleep apnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Use with caution in patients receiving other CNS depressants; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid doses &gt;6 mg/day in this age group due to its potent anticholinergic and sedative properties, and potential to cause orthostatic hypotension; safety of doses &le;6 mg/day is comparable to placebo. In addition, may also cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8082284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: A high-fat meal increases the bioavailability of Silenor&reg; and delays the peak plasma concentration by ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10827783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8082269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased fetal body weight and fetal structural abnormalities were observed in animal reproduction studies at doses greater than the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8082270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8082271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness and apnea have been reported in a nursing infant following maternal use of doxepin for depression.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8082352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Doxepin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $32.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $42.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $56.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $117.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $102.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (90): $299.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Doxepin HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (120 mL): $23.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Silenor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (30): $198.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (30): $198.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8082239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and pulse rate prior to and during initial therapy; monitor mental status, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased); weight; ECG in older adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Insomnia: Re-evaluate diagnosis if insomnia does not remit within 7-10 days of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8082300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Proposed therapeutic concentration (doxepin plus desmethyldoxepin): 110-250 ng/mL. Toxic concentration (doxepin plus desmethyldoxepin): &gt;500 ng/mL. Utility of serum level monitoring is controversial.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anten (NZ);",
"     </li>",
"     <li>",
"      Deptran (AU);",
"     </li>",
"     <li>",
"      Doneurin (DE);",
"     </li>",
"     <li>",
"      Doxal (FI);",
"     </li>",
"     <li>",
"      Doxin (IN);",
"     </li>",
"     <li>",
"      Espadox (DE);",
"     </li>",
"     <li>",
"      Expan (CO);",
"     </li>",
"     <li>",
"      Gilex (IL);",
"     </li>",
"     <li>",
"      Mareen (DE);",
"     </li>",
"     <li>",
"      Qualiquan (HK);",
"     </li>",
"     <li>",
"      Quitaxon (FR);",
"     </li>",
"     <li>",
"      Sinepin (GB);",
"     </li>",
"     <li>",
"      Sinequan (AT, AU, BE, GR, HK, NL, NO, TH, TW);",
"     </li>",
"     <li>",
"      Sinquan (CH, DE, DK);",
"     </li>",
"     <li>",
"      Spectra (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8082298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane; antagonizes the histamine (H",
"     <sub>",
"      1",
"     </sub>",
"     ) receptor for sleep maintenance",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8082301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Antidepressant: Usually &gt;2 weeks; Anxiolytic: may occur sooner",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C19 and 2D6; metabolites include N-desmethyldoxepin (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: Doxepin: ~15 hours; N-desmethyldoxepin: 31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Hypnotic: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;3% as unchanged drug or N-desmethyldoxepin)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(849):311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jefferson JW, &ldquo;Tamoxifen-Associated Reduction in Tricyclic Antidepressant Levels in Blood,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1995, 15(3):223-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lakshmanan M, Mion LC, and Frengley JD, &ldquo;Effective Low-Dose Tricyclic Antidepressant Treatment for Depressed Geriatric Rehabilitation Patients. A Double-Blind Study,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(6):421-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/3700932/pubmed\" id=\"3700932\" target=\"_blank\">",
"        3700932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JR, &ldquo;Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1970, 49(8):1596-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/5431666/pubmed\" id=\"5431666\" target=\"_blank\">",
"        5431666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/32/44551/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin&reg; in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9112 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44551=[""].join("\n");
var outline_f43_32_44551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082208\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10570484\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082262\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082558\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082233\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082234\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804890\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082235\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082350\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082264\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082214\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082237\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082265\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082267\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082213\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082276\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082272\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082273\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082279\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082280\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082284\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827783\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082269\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082270\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082271\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082352\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082239\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082300\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962014\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082298\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082301\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9112\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9112|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/8/40069?source=related_link\">",
"      Doxepin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/59/24503?source=related_link\">",
"      Doxepin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/8/14470?source=related_link\">",
"      Doxepin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/23/20852?source=related_link\">",
"      Doxepin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/54/14181?source=related_link\">",
"      Doxepin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_32_44552="Infections of central nervous system shunts and other devices";
var content_f43_32_44552=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infections of central nervous system shunts and other devices",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Patricia M Flynn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Thomas Fekete, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44552/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/32/44552/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid (CSF) shunts are used in the setting of hydrocephalus to divert CSF to another part of the body for absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/1\">",
"     1",
"    </a>",
"    ]. The approach to management of shunt infections is discussed here. Indications for shunt placement and other issues related to hydrocephalus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=see_link\">",
"     \"Hydrocephalus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14762?source=see_link\">",
"     \"Normal pressure hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SHUNT DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal portion of the shunt catheter is most commonly placed in one of the cerebral ventricles, but may also be placed in an intracranial cyst or the lumbar subarachnoid space. The distal portion of the shunt can be internalized or externalized. Internalized shunts most commonly drain into the peritoneum (ventriculoperitoneal or VP shunt), although less commonly they drain into the vascular space (ventriculoatrial or VA shunt).",
"   </p>",
"   <p>",
"    Externalized devices (ventriculostomy catheters, also called external ventricular drains or EVDs) are temporary devices typically placed in the setting of acute hydrocephalus for intracranial pressure monitoring and therapeutic diversion of CSF. They may also be placed for interim management of hydrocephalus during antibiotic therapy for an infected internalized device that has been removed.",
"   </p>",
"   <p>",
"    Other externalized CNS devices such as Ommaya reservoirs (for administration of antimicrobial drugs or cancer chemotherapy) can also become infected. The proximal portion of these devices is typically placed in the intraventricular space, but may also be placed in an abscess cavity or tumor. The distal portion of the device is a reservoir placed under the scalp (less commonly in the lumbar space) and accessed via a needle when needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of internalized device infection ranges from 5 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/2-12\">",
"     2-12",
"    </a>",
"    ]. The highest infection rates have been observed during the initial month after placement, in patients requiring serial revisions, and in patients undergoing revision after treatment for an infected shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/3,11\">",
"     3,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of externalized device infection ranges from 5 to 10 percent. Factors associated with increased risk of infection include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/7,13-16\">",
"     7,13-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intraventricular hemorrhage",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage",
"     </li>",
"     <li>",
"      Cranial fracture with CSF leak",
"     </li>",
"     <li>",
"      Craniotomy",
"     </li>",
"     <li>",
"      Ventriculostomy catheter irrigation",
"     </li>",
"     <li>",
"      Duration of catheterization (eg, higher risk if device remains in place longer than three to five days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shunt infections most frequently develop via colonization of the shunt with skin flora. This may occur at the time of surgery or postoperatively via breakdown of the wound or overlying skin. These infections occur in the early weeks after shunt placement, and staphylococci are the predominant pathogens. Early infection with skin flora is the most common type of CNS shunt infection; about half of all shunt infections are due to coagulase-negative staphylococci and about a third of cases are due to Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/4,8,11,17-20\">",
"     4,8,11,17-20",
"    </a>",
"    ]. Diphtheroids (such as Propionibacterium acnes and Corynebacterium jeikeium) may also be pathogenic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9672?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shunt infections may also develop via direct contamination of the distal end of the shunt or via hematogenous seeding. Distal end contamination of VP shunts occurs in the setting of bowel perforation or peritonitis, whereas contamination of externalized devices occurs via catheter irrigation or tracking of microorganisms along the exit site. These infections tend to occur months after shunt placement and account for about 10 to 15 percent of shunt infections. They may be due to a variety of organisms including streptococci, gram-negative bacteria (including Pseudomonas aeruginosa), anaerobes, mycobacteria and fungi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/13,21-33\">",
"     13,21-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shunt infections can present with few or no symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/34\">",
"     34",
"    </a>",
"    ]. In some cases, symptoms develop only when infection has caused shunt obstruction and subsequent malfunction with clinical signs of increased intracranial pressure (eg, headache,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    lethargy, or altered mental status). Meningeal symptoms may not be observed, because communication between the infected ventricles and the meninges is usually absent (this is the reason for the shunt). Fever may or may not be present.",
"   </p>",
"   <p>",
"    Symptoms may also present with localization to the distal internal (VP or VA shunts) or external end of the shunt:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventriculoperitoneal (VP) shunt infections may manifest with symptoms of peritonitis, including fever, abdominal pain, and anorexia. Large loculated pockets can develop in the peritoneum because of diminished CSF absorption in the setting of inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7172?source=see_link\">",
"       \"Clinical manifestations of spontaneous bacterial peritonitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventriculoatrial (VA) shunt infections may present with fever and evidence of bloodstream infection, which may develop via entry of infected CSF into the bloodstream or from an infected thrombus at the catheter tip. Subsequent endocarditis and its concomitant sequelae can occur, including septic pulmonary emboli and antibody-mediated sequelae such as glomerulonephritis and dermatologic manifestations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Distal external shunt infections typically present as evidence of soft tissue infection with swelling, erythema, tenderness or purulent drainage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If clinical manifestations suggest the possibility of infection, a diagnostic evaluation should be initiated with cerebrospinal fluid analysis, blood cultures, and imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct aspiration of the shunt is preferred over ventricular tap or lumbar puncture when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/17,37\">",
"     17,37",
"    </a>",
"    ]. The CSF should be examined for white cell count with differential, glucose and protein concentrations, Gram stain, and culture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\", section on 'CSF analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interpretation of CSF parameters can be challenging, and no single clinical or laboratory parameter, including fever, leukocytosis, pleocytosis, or CSF protein and glucose, can reliably predict or exclude a shunt infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/38\">",
"     38",
"    </a>",
"    ]. CNS device-related infections often manifest with less inflammation than bacterial meningitis; as a result, cell count abnormalities may be subtle and difficult to distinguish from postoperative inflammation. In a retrospective report of 11 pediatric shunt infections, for example, five had CSF white blood cell counts less than",
"    <span class=\"nowrap\">",
"     12/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The white cell differential may be a useful clue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In one report of 129 shunt placements, a white cell count differential with &gt;10 percent neutrophils was 90 percent sensitive for predicting infection; the negative predictive value was 0.99. Presence of eosinophils is rare and should raise the possibility inflammation due to shunt malfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSF culture results are critical for organism identification and directing antibiotic therapy. However, CSF cultures may be falsely positive in the absence of other CSF abnormalities. In these instances, the isolates may represent contaminants and should be interpreted together with other clinical and laboratory parameters in determining management. Repeatedly positive cultures several days are unlikely to represent contaminants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine prospective CSF analysis has little value in predicting infection and may increase the risk of iatrogenic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In a prospective study of 230 patients, for example, routine analysis of CSF did not predict subsequent external drain-related infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/42\">",
"     42",
"    </a>",
"    ]. The sensitivity of CSF Gram stain was 18 percent on the first day of infection and 60 percent on the second day; the specificity of CSF Gram stain was 99 percent. Thus, a positive Gram stain can be quite helpful but a negative one is less useful. Infections are not presaged by specific and reproducible changes in CSF parameters.",
"   </p>",
"   <p>",
"    Some authors suggest surveillance CSF analysis when the predisposing diagnosis is associated with an increased risk of infection, such as subarachnoid hemorrhage, intraventricular hemorrhage, or cranial fracture with leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/14\">",
"     14",
"    </a>",
"    ]. Hyperthermia due to these underlying conditions can confound an already difficult clinical examination. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Incidence and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Others advocate CSF analysis only when infection is suspected on clinical grounds. In all cases, positive cultures should be correlated with Gram stain and CSF analysis to avoid unnecessary treatment for skin florae that do not represent true pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures should be obtained along with CSF analysis when shunt infection is suspected. Their yield is much higher in the setting of ventriculoatrial shunts (VA) than ventriculoperitoneal (VP) shunts (95 versus 23 percent in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/17,35\">",
"     17,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging studies can be useful to look for evidence of ventriculitis or CSF obstruction (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    ). Abdominal imaging (computed tomography or ultrasound) may be useful to identify CSF loculations at the distal end of VP shunts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized, prospective trials addressing optimal treatment of CNS shunt infections. Management of CNS shunt infection should include removal of the device, external drainage, parenteral antibiotics, and shunt replacement once the CSF is sterile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. If device removal is not feasible, intraventricular antibiotics may be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Intraventricular antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Device removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of CNS shunt infection should include removal of the device, external drainage, and subsequent shunt replacement once CSF is sterile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/45,46,48\">",
"     45,46,48",
"    </a>",
"    ]. In one retrospective review of 50 CNS shunt infections, for example, 22 patients were treated with shunt removal, external drainage, and antibiotics; 17 patients were managed with shunt removal followed by immediate shunt replacement and antibiotics; and 11 patients received antibiotics without shunt removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/46\">",
"     46",
"    </a>",
"    ]. The response rates were 95, 65 and 35 percent, respectively.",
"   </p>",
"   <p>",
"    Management of intracranial pressure during the interval of device removal requires careful coordination between neurosurgeons and infectious disease consultants, particularly in shunt-dependent who require external drainage to control intracranial hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral antibiotic selection should be guided by the results of CSF Gram stain and culture. Pending these results, empiric therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and an agent to cover gram-negative pathogens. For adults, an agent to cover nosocomial gram-negative pathogens (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ) is appropriate. For children, an agent to cover endogenous gram-negative pathogens (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ) is appropriate.",
"   </p>",
"   <p>",
"    Subsequent antibiotic therapy should be tailored to culture and susceptibility results. For gram-positive isolates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    monotherapy should be continued for methicillin-resistant pathogens, while methicillin susceptible pathogens should be managed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    . Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    is not routinely added to the above regimens, but may augment treatment in the setting of refractory cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    have also been used to treat CNS shunt infections, although they are not first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatments for gram negative bacillary infection and for Candida infection are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\", section on 'Treatment recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39559?source=see_link&amp;anchor=H4#H4\">",
"     \"Candida infections of the central nervous system\", section on 'CNS shunts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosing of antibiotics for meningitis in neonates, children and adults is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16121?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Antimicrobial therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Empiric therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=see_link\">",
"     \"Initial therapy and prognosis of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Intraventricular antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled trials of the efficacy of intraventricular antibiotics in central nervous system device infections have been performed. This treatment modality is potentially toxic and requires careful preparation and delivery to avoid contamination. It should therefore be reserved for circumstances in which conventional intravenous therapy has failed. It may be useful in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of parenteral therapy to sterilize the CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of highly resistant organisms sensitive only to antibiotics with poor CSF penetration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Circumstances in which shunt devices cannot be removed (including infected Ommaya reservoirs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/10,55,56\">",
"       10,55,56",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no antibiotics that have been approved by the US Food and Drug administration for intraventricular use. The greatest clinical experience has been with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ; the use of other agents has generally been limited to case reports (",
"    <a class=\"graphic graphic_table graphicRef71395 \" href=\"mobipreview.htm?8/53/9052\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/22,54-61\">",
"     22,54-61",
"    </a>",
"    ]. In one study",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    10 mg was administered every 12 hours intrathecally without an increase in observed toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/62\">",
"     62",
"    </a>",
"    ]. Penicillins and cephalosporins should not be given by the intraventricular route because of significant neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/54,63\">",
"     54,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no standardized approach to intraventricular antibiotic dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Empiric initial doses are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef71395 \" href=\"mobipreview.htm?8/53/9052\">",
"     table 1",
"    </a>",
"    ). Subsequent dosing to ensure adequate CSF concentrations has been guided by calculation of the \"inhibitory quotient\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/43\">",
"     43",
"    </a>",
"    ]. This can be determined by dividing the trough CSF antibiotic concentration by the MIC of the drug for the isolate; it should not exceed 10 to 20. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\", section on 'Intrathecal and intraventricular therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antibiotic duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized, prospective trials have been performed to determine the optimal duration of antibiotic therapy and the timing of device replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The suggested approach varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the device is removed in the setting of normal CSF chemistries and CSF cultures positive for coagulase-negative staphylococci (eg, findings that may represent colonization), the shunt may be replaced if cultures are negative on the third day after removal.",
"     </li>",
"     <li>",
"      In patients with coagulase negative staphylococci and concomitant abnormal CSF chemistries, antibiotics should be administered for the total time the device remains in place and for at least one additional week following removal. The CSF should be sterile prior to shunt replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Shunt infections with more virulent pathogens such as S. aureus and gram-negative bacilli warrant longer therapy; at least 10 days for S. aureus and perhaps 14 to 21 days for gram-negative bacilli. The CSF should be sterile for 10 days prior to shunt replacement. In addition, some advocate a few days of clinical observation off antibiotics prior to shunt replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the device is not removed, antibiotics should be administered for at least 7 to 10 days after sterilization of the CSF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decisions regarding antibiotic duration should be tailored to an individual patient's response to therapy; longer courses may be warranted in the setting of delayed or incomplete response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures for prevention of CNS shunt infection include careful adherence to sterile technique (including topical antiseptic) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/66\">",
"     66",
"    </a>",
"    ] and perioperative antibiotic prophylaxis with parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . Antibiotic impregnated catheters may be beneficial, and prophylactic catheter exchange is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative antibiotic prophylaxis is warranted in the initial 24 hours after device placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. There are no randomized controlled trials addressing this practice; a meta-analysis of 15 observational studies concluded that use of systemic prophylactic antibiotics decreases rates of shunt infection (odds ratio [OR] 0.52, 95% CI 0.36-0.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the predominant role of coagulase-negative staphylococci in CNS shunt infections,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is advisable over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    for prophylaxis. Vancomycin should be administered as 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (not to exceed 2 g per dose) intravenously two hours prior to device placement with one additional dose given 12 hours later. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Neurosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotic-impregnated catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic-impregnated devices may be useful for reducing incidence of CNS shunt infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/67,71-74\">",
"     67,71-74",
"    </a>",
"    ]. In a randomized trial of 288 device placements, for example, patients who received antibiotic-impregnated catheters were less likely to develop positive CSF cultures than those who received control catheters (1 versus 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/73\">",
"     73",
"    </a>",
"    ]. A significant reduction in shunt infection with these catheters was also noted in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/67\">",
"     67",
"    </a>",
"    ]. However, the authors concluded that more well-designed clinical trials were required to confirm the benefit. Similar concerns have been raised about antibiotic-impregnated central venous catheters. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H1923683666#H1923683666\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Antimicrobial impregnated catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prophylactic catheter exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic catheter exchange is not effective for preventing CNS shunt infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/14,67,75,76\">",
"     14,67,75,76",
"    </a>",
"    ]. In a trial of 103 patients randomly assigned to prophylactic catheter exchange or control groups, for example, there was no difference in shunt infection rates (8 versus 4 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/75\">",
"     75",
"    </a>",
"    ]. Similar lack of benefit was noted in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44552/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of CNS shunt infection is about 5 to 15 percent. Risk factors include intraventricular hemorrhage, subarachnoid hemorrhage and cranial fracture with CSF leak. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin flora account for the majority of infections associated with internalized or externalized CNS shunt devices. Shunt infections may also develop from the distal ends of internalized devices, leading to peritonitis or bloodstream infection with a variety of pathogens. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology and Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations may be subtle or absent. They may present as manifestations of increased intracranial pressure or with symptoms localized to the distal end of the device. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of CNS shunt infection can be challenging; CSF cell counts may be low and should be correlated with Gram stain and culture results. Blood cultures and imaging studies may be useful adjunctive tools. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that surgical management of CNS shunt infection include device removal (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), establishment of external drainage (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ), and placement of a new shunt once CSF is sterile (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend initiating empiric parenteral antibiotic therapy for coverage of coagulase-negative staphylococci and nosocomial gram-negative pathogens (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest intraventricular antibiotics if parenteral therapy fails to sterilize the CSF or in the setting of highly resistant organisms sensitive only to antibiotics with poor CSF penetration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Intraventricular antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The duration of antibiotic therapy depends upon the implicated pathogen and presence of retained hardware. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibiotic duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend perioperative antibiotic prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Vancomycin should be administered as 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously two hours prior to device placement with one additional dose given 12 hours later. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of antibiotic impregnated catheters for prevention of CNS shunt infections (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We recommend against prophylactic catheter exchange for prevention of infection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tunkel AR, Kaufman BA. Cerebrospinal Fluid Shunt Infections. In: Principles and Practice of Infectious Diseases, 6, Mandell GL, Bennett JE, Dolin R (Eds), Elsevier Inc, Philadelphia 2005. p.1126.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/2\">",
"      Rotim K, Miklic P, Paladino J, et al. Reducing the incidence of infection in pediatric cerebrospinal fluid shunt operations. Childs Nerv Syst 1997; 13:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/3\">",
"      Borgbjerg BM, Gjerris F, Albeck MJ, B&oslash;rgesen SE. Risk of infection after cerebrospinal fluid shunt: an analysis of 884 first-time shunts. Acta Neurochir (Wien) 1995; 136:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/4\">",
"      Davis SE, Levy ML, McComb JG, Masri-Lavine L. Does age or other factors influence the incidence of ventriculoperitoneal shunt infections? Pediatr Neurosurg 1999; 30:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/5\">",
"      Lam CH, Villemure JG. Comparison between ventriculoatrial and ventriculoperitoneal shunting in the adult population. Br J Neurosurg 1997; 11:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/6\">",
"      Kulkarni AV, Drake JM, Lamberti-Pasculli M. Cerebrospinal fluid shunt infection: a prospective study of risk factors. J Neurosurg 2001; 94:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/7\">",
"      Mayhall CG, Archer NH, Lamb VA, et al. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med 1984; 310:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/8\">",
"      McGirt MJ, Zaas A, Fuchs HE, et al. Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens. Clin Infect Dis 2003; 36:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/9\">",
"      Lishner M, Perrin RG, Feld R, et al. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med 1990; 150:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/10\">",
"      Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/11\">",
"      George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg 1979; 51:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/12\">",
"      Simon TD, Hall M, Riva-Cambrin J, et al. Infection rates following initial cerebrospinal fluid shunt placement across pediatric hospitals in the United States. Clinical article. J Neurosurg Pediatr 2009; 4:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/13\">",
"      Lyke KE, Obasanjo OO, Williams MA, et al. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. Clin Infect Dis 2001; 33:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/14\">",
"      Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery 2002; 51:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/15\">",
"      Dallacasa P, Dappozzo A, Galassi E, et al. Cerebrospinal fluid shunt infections in infants. Childs Nerv Syst 1995; 11:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/16\">",
"      Aucoin PJ, Kotilainen HR, Gantz NM, et al. Intracranial pressure monitors. Epidemiologic study of risk factors and infections. Am J Med 1986; 80:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/17\">",
"      Schoenbaum SC, Gardner P, Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis 1975; 131:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/18\">",
"      Nelson JD. Cerebrospinal fluid shunt infections. Pediatr Infect Dis 1984; 3:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/19\">",
"      Younger JJ, Christensen GD, Bartley DL, et al. Coagulase-negative staphylococci isolated from cerebrospinal fluid shunts: importance of slime production, species identification, and shunt removal to clinical outcome. J Infect Dis 1987; 156:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/20\">",
"      Diaz-Mitoma F, Harding GK, Hoban DJ, et al. Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci. J Infect Dis 1987; 156:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/21\">",
"      Filka J, Huttova M, Tuharsky J, et al. Nosocomial meningitis in children after ventriculoperitoneal shunt insertion. Acta Paediatr 1999; 88:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/22\">",
"      Segal-Maurer S, Mariano N, Qavi A, et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999; 28:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/23\">",
"      Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998; 26:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/24\">",
"      Vinchon M, Lemaitre MP, Vall&eacute;e L, Dhellemmes P. Late shunt infection: incidence, pathogenesis, and therapeutic implications. Neuropediatrics 2002; 33:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/25\">",
"      Baird C, O'Connor D, Pittman T. Late shunt infections. Pediatr Neurosurg 1999; 31:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/26\">",
"      Greene KA, Clark RJ, Zabramski JM. Ventricular CSF shunt infections associated with Corynebacterium jeikeium: report of three cases and review. Clin Infect Dis 1993; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/27\">",
"      Knudsen JD, Nielsen CJ, Espersen F. Treatment of shunt-related cerebral ventriculitis due to Corynebacterium jeikeium with vancomycin administered intraventricularly. Case report. APMIS 1994; 102:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/28\">",
"      Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg 1997; 87:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/29\">",
"      Bremer AA, Darouiche RO. Ventriculoperitoneal shunt infection due to Serratia marcescens. J Infect 2005; 50:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/30\">",
"      Christenson JC, Pavia AT, Seskin K, et al. Meningitis due to Ochrobactrum anthropi: an emerging nosocomial pathogen. A report of 3 cases. Pediatr Neurosurg 1997; 27:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/31\">",
"      Berner R, Heinen F, Pelz K, et al. Ventricular shunt infection and meningitis due to Bacillus cereus. Neuropediatrics 1997; 28:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/32\">",
"      Midani S, Rathore MH. Mycobacterium fortuitum infection of ventriculoperitoneal shunt. South Med J 1999; 92:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/33\">",
"      Chiou CC, Wong TT, Lin HH, et al. Fungal infection of ventriculoperitoneal shunts in children. Clin Infect Dis 1994; 19:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/34\">",
"      Conen A, Walti LN, Merlo A, et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008; 47:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/35\">",
"      Forward KR, Fewer HD, Stiver HG. Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients. J Neurosurg 1983; 59:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/36\">",
"      Arze RS, Rashid H, Morley R, et al. Shunt nephritis: report of two cases and review of the literature. Clin Nephrol 1983; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/37\">",
"      Noetzel MJ, Baker RP. Shunt fluid examination: risks and benefits in the evaluation of shunt malfunction and infection. J Neurosurg 1984; 61:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/38\">",
"      Meredith FT, Phillips HK, Reller LB. Clinical utility of broth cultures of cerebrospinal fluid from patients at risk for shunt infections. J Clin Microbiol 1997; 35:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/39\">",
"      McClinton D, Carraccio C, Englander R. Predictors of ventriculoperitoneal shunt pathology. Pediatr Infect Dis J 2001; 20:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/40\">",
"      Lan CC, Wong TT, Chen SJ, et al. Early diagnosis of ventriculoperitoneal shunt infections and malfunctions in children with hydrocephalus. J Microbiol Immunol Infect 2003; 36:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/41\">",
"      Hader WJ, Steinbok P. The value of routine cultures of the cerebrospinal fluid in patients with external ventricular drains. Neurosurgery 2000; 46:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/42\">",
"      Schade RP, Schinkel J, Roelandse FW, et al. Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. J Neurosurg 2006; 104:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/43\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/44\">",
"      Whitehead WE, Kestle JR. The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons. Pediatr Neurosurg 2001; 35:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/45\">",
"      James HE, Walsh JW, Wilson HD, et al. Prospective randomized study of therapy in cerebrospinal fluid shunt infection. Neurosurgery 1980; 7:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/46\">",
"      James HE, Walsh JW, Wilson HD, Connor JD. The management of cerebrospinal fluid shunt infections: a clinical experience. Acta Neurochir (Wien) 1981; 59:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/47\">",
"      Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002; 21:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/48\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/49\">",
"      Gombert ME, Landesman SH, Corrado ML, et al. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J Neurosurg 1981; 55:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/50\">",
"      Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002; 46:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/51\">",
"      Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/52\">",
"      Williamson JC, Glazier SS, Peacock JE Jr. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Clin Neurol Neurosurg 2002; 104:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/53\">",
"      Tan TY, Pitman I, Penrose-Stevens A, et al. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature. J Infect 2000; 41:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/54\">",
"      Wen DY, Bottini AG, Hall WA, Haines SJ. Infections in neurologic surgery. The intraventricular use of antibiotics. Neurosurg Clin N Am 1992; 3:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/55\">",
"      Lishner M, Scheinbaum R, Messner HA. Intrathecal vancomycin in the treatment of Ommaya reservoir infection by Staphylococcus epidermidis. Scand J Infect Dis 1991; 23:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/56\">",
"      Sutherland GE, Palitang EG, Marr JJ, Luedke SL. Sterilization of Ommaya reservoir by instillation of vancomycin. Am J Med 1981; 71:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/57\">",
"      Swayne R, Rampling A, Newsom SW. Intraventricular vancomycin for treatment of shunt-associated ventriculitis. J Antimicrob Chemother 1987; 19:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/58\">",
"      Nguyen MH, Harris SP, Muder RR, Pasculle AW. Antibiotic-resistant Acinetobacter meningitis in neurosurgical patients. Neurosurgery 1994; 35:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/59\">",
"      Gump WC, Walsh JW. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature. J Neurosurg 2005; 102:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/60\">",
"      Quinn AL, Parada JP, Belmares J, O'Keefe JP. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother 2005; 39:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/61\">",
"      Cruciani M, Navarra A, Di Perri G, et al. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Clin Infect Dis 1992; 15:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/62\">",
"      Rodr&iacute;guez Guardado A, Blanco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 2008; 61:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/63\">",
"      Manzella JP, Paul RL, Butler IL. CNS toxicity associated with intraventricular injection of cefazolin. Report of three cases. J Neurosurg 1988; 68:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/64\">",
"      Wald SL, McLaurin RL. Cerebrospinal fluid antibiotic levels during treatment of shunt infections. J Neurosurg 1980; 52:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/65\">",
"      James HE, Wilson HD, Connor JD, Walsh JW. Intraventricular cerebrospinal fluid antibiotic concentrations in patients with intraventricular infections. Neurosurgery 1982; 10:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/66\">",
"      Choksey MS, Malik IA. Zero tolerance to shunt infections: can it be achieved? J Neurol Neurosurg Psychiatry 2004; 75:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/67\">",
"      Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. Cochrane Database Syst Rev 2006; :CD005365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/68\">",
"      Prabhu VC, Kaufman HH, Voelker JL, et al. Prophylactic antibiotics with intracranial pressure monitors and external ventricular drains: a review of the evidence. Surg Neurol 1999; 52:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/69\">",
"      Morris A, Low DE. Nosocomial bacterial meningitis, including central nervous system shunt infections. Infect Dis Clin North Am 1999; 13:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/70\">",
"      Ragel BT, Browd SR, Schmidt RH. Surgical shunt infection: significant reduction when using intraventricular and systemic antibiotic agents. J Neurosurg 2006; 105:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/71\">",
"      Aryan HE, Meltzer HS, Park MS, et al. Initial experience with antibiotic-impregnated silicone catheters for shunting of cerebrospinal fluid in children. Childs Nerv Syst 2005; 21:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/72\">",
"      Govender ST, Nathoo N, van Dellen JR. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. J Neurosurg 2003; 99:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/73\">",
"      Zabramski JM, Whiting D, Darouiche RO, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg 2003; 98:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/74\">",
"      Kaufmann AM, Lye T, Redekop G, et al. Infection rates in standard vs. hydrogel coated ventricular catheters. Can J Neurol Sci 2004; 31:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/75\">",
"      Wong GK, Poon WS, Wai S, et al. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry 2002; 73:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44552/abstract/76\">",
"      Holloway KL, Barnes T, Choi S, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J Neurosurg 1996; 85:419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1286 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-115.25.216.6-56B6879C82-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44552=[""].join("\n");
var outline_f43_32_44552=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SHUNT DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Device removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Intraventricular antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antibiotic duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotic-impregnated catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prophylactic catheter exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1286\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1286|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/53/9052\" title=\"table 1\">",
"      Intraventricular dosing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39559?source=related_link\">",
"      Candida infections of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7172?source=related_link\">",
"      Clinical manifestations of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22810?source=related_link\">",
"      Initial therapy and prognosis of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9672?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14762?source=related_link\">",
"      Normal pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_32_44553="Overview of central venous access";
var content_f43_32_44553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of central venous access",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Alan C Heffner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Mark P Androes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44553/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/32/44553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous access is a commonly performed procedure with approximately 8 percent of hospitalized patients requiring central venous access to place a central venous catheter during the course of their hospital stay. More than five million central venous catheters are inserted in the United States each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central venous access is also needed to place pulmonary artery catheters, plasmapheresis and hemodialysis catheters, as well as to place inferior vena cava filters, introduce wires for transvenous pacing and defibrillator devices, and for venous interventions. The central venous access site and manner in which access is achieved depends upon the indication for placement, patient anatomy, and other patient-related factors.",
"   </p>",
"   <p>",
"    The indications for central venous access, types of central catheters, catheter selection, site selection, and general issues of preparation and placement will be reviewed here. The role of catheters and devices for monitoring cardiac parameters, or administering chemotherapy or parenteral nutrition is discussed in separate topic reviews.",
"   </p>",
"   <p>",
"    The placement of jugular, subclavian and femoral catheters, issues specific to these anatomic sites and routine maintenance and care of catheters and port devices and complications of central venous catheters and related devices are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103243\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common indications for the placement of central catheters include [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/3\">",
"       3",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Administration of noxious medications &ndash; Medications such as vasopressors, chemotherapy, and parenteral nutrition are given by central venous catheters because they can cause vein inflammation (phlebitis) when given through a peripheral intravenous catheter.",
"     </li>",
"     <li>",
"      Hemodynamic monitoring &ndash; Central venous access permits measurement of the central venous pressure, venous oxyhemoglobin saturation and cardiac parameters (via pulmonary artery catheter).",
"     </li>",
"     <li>",
"      Plasmapheresis, apheresis, hemodialysis, or continuous renal replacement therapy",
"     </li>",
"     <li>",
"      Poor peripheral venous access",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Venous access is also needed to place venous devices and for venous interventions including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Transvenous cardiac pacing",
"     </li>",
"     <li>",
"      Inferior vena cava filter placement",
"     </li>",
"     <li>",
"      Venous thrombolytic therapy, venous stenting",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to central venous catheterization are relative and depend upon the urgency and alternatives for venous access. Cannulation is generally avoided at sites with anatomic distortion or other indwelling intravascular hardware, such as a pacemaker, or hemodialysis catheter. Injury proximal to the insertion site represents another relative contraindication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177530472\">",
"    <span class=\"h2\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulopathy is a relative contraindication to central venous catheterization, although significant bleeding is uncommon. The safety of large-bore tunneled catheter placement has been documented in patients with mild-to-moderate coagulation abnormalities. Thrombocytopenia poses a greater risk compared with a prolonged clotting time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, non-tunneled catheters placed at sites that are easy to monitor for bleeding are preferred in patients with coagulopathy. A subclavian approach should generally be avoided in patients at risk for bleeding due to an inability to effectively monitor or compress the venipuncture site. &nbsp;",
"   </p>",
"   <p>",
"    Fresh frozen plasma or platelets can be administered prior to the procedure in patients with severe coagulation abnormalities to reduce the risk of bleeding complications, but there is little evidence to support this practice. The indications for correcting coagulation abnormalities in patients undergoing invasive procedures and dosing, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19385?source=see_link&amp;anchor=H33#H33\">",
"     \"Evaluation and management of thrombocytopenia by primary care physicians\", section on 'Invasive procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical use of plasma components\", section on 'Fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103752\">",
"    <span class=\"h1\">",
"     CENTRAL CATHETERS AND DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheters can be inserted percutaneously or surgically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103759\">",
"    <span class=\"h2\">",
"     Non-tunneled",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-tunneled central catheters are placed percutaneously with the catheter exiting the skin in the vicinity of the venous cannulation site. These catheters are the most common type of catheter used for temporary access to the central circulation. Catheters are available in a variety of lengths (15 to 30 cm) and catheter materials (eg, polyurethane, silicone). Specialized catheters for longer-term infusion may contain a valve mechanism to limit backflow of blood for the purpose of preventing infection and catheter thrombosis. Power injectable catheters for administration of intravenous contrast are also available.",
"   </p>",
"   <p>",
"    Non-tunneled central catheters may be single, double, or even triple lumen. The different lumens infuse fluid through holes located on the side of the catheter. The end hole is more reliable for drawing blood because the end hole is less likely to be suctioned against the wall of the vein compared with the side holes. As the number of lumens increase, the overall diameter of the catheter increases, and the diameter of the individual luminal channels decreases. The use of multilumen catheters reduces the maximum infusion rate of the catheter and increases the rate of catheter thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link&amp;anchor=H165302905#H165302905\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Catheter-related factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another type of central catheter is the peripherally inserted central catheter (PICC). These central devices are gaining in popularity due to the relative ease of insertion into the upper arm veins (cephalic or basilic veins) (",
"    <a class=\"graphic graphic_figure graphicRef55596 \" href=\"mobipreview.htm?18/3/18480\">",
"     figure 1",
"    </a>",
"    ), a lower risk of some complications, and good patient tolerance. Single and double lumen PICC catheters and valved devices are also available. PICC lines devices are less favored in patients with significant renal dysfunction due to the potential for central venous thrombosis or stenosis, or peripheral venous stenosis that could complicate long-term access options for hemodialysis; however, the incidence of this potential complication is not well established. As with centrally-inserted catheters, the rate of venous thrombosis for PICC catheters increases with an increasing number of lumens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link&amp;anchor=H165302905#H165302905\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Catheter-related factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An introducer sheath is a special type of venous access catheter that is single-lumen, but with a larger bore (8.5 F) and shorter length than standard central catheters. The proximal end of these devices contains a hemostatic valve through which other devices are introduced into the venous circulation (eg, pulmonary artery catheter). However, the device can be used alone for rapid fluid infusion due to the large luminal diameter. (See",
"    <a class=\"local\" href=\"#H3103773\">",
"     'Specialized venous devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antibiotic and antiseptic-impregnated central catheters are available, and may decrease rates of bacterial colonization and catheter-related infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H1923683666#H1923683666\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Antimicrobial impregnated catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103766\">",
"    <span class=\"h2\">",
"     Implanted",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implanted catheters are meant to be semipermanent with removal reserved if complications occur or the device is no longer needed (eg, completion of chemotherapy). Two types of implanted central venous catheters are available, tunneled catheters and totally implantable venous access devices. Power injectable tunneled catheters and port devices are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362076169\">",
"    <span class=\"h3\">",
"     Tunneled",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tunneled central venous catheters traverse a subcutaneous tunnel between the catheterized vein and the skin exit site. The catheter may be round or flat and catheter sizes can range from 2.7 to 12.5 F (eg, Hickman, Broviac). A cuff (velour, Dacron) is positioned in the subcutaneous tissue adjacent the exit site. In general, rates of infection associated with tunneled catheters are lower than those reported with the use of non-tunneled central venous catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/5\">",
"     5",
"    </a>",
"    ]. Dialysis and pheresis catheters are specialized large-bore double lumen catheters designed for the exchange of large volumes of blood at high flow rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Determinants of infection risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link&amp;anchor=H79680952#H79680952\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Dialysis catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H362076162\">",
"    <span class=\"h3\">",
"     Subcutaneous port",
"    </span>",
"    &nbsp;&mdash;&nbsp;Totally implantable venous access devices have been used widely since their introduction in the 1980s (eg, Port-a-Cath, BardPort, PowerPort, Infuse-a-Port, Medi-port) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The catheter of these devices is passed from the cannulated vein beneath the skin and attached to a subcutaneous infusion port or reservoir that is placed into a subcutaneous pocket. PICC devices can also be attached to a subcutaneous port (eg, Passport).",
"   </p>",
"   <p>",
"    The port or reservoir is accessed through the skin by needle puncture into the port&rsquo;s self-sealing septum. Single and dual port devices are available. The main factor limiting infusion rate with these devices is the bore of the access needle (eg, Huber, 19 [0.053&rdquo; = 1.33 mm diameter] to 22 gauge [0.045&rdquo; = 1.2 mm diameter]), which is nearly always smaller than the internal diameter of the catheter attached to the port. Subcutaneous ports are commonly used to administer chemotherapy agents because of their low rates of extravasation and infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/10\">",
"     10",
"    </a>",
"    ]. Subcutaneous ports also have the advantage that the device is hidden from view, and thus, this option is more cosmetically appealing. Magnetic resonance compatible devices are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103773\">",
"    <span class=\"h2\">",
"     Specialized venous devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medical devices are placed into the venous circulation after first gaining access to the central venous circulation. These devices are typically placed through an introducer sheath. (See",
"    <a class=\"local\" href=\"#H3103759\">",
"     'Non-tunneled'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vena cava filters &ndash; Vena cava filters (",
"      <a class=\"graphic graphic_figure graphicRef69737 \" href=\"mobipreview.htm?4/48/4868\">",
"       figure 2",
"      </a>",
"      ) are indicated to decrease the risk of fatal pulmonary embolism in selected patients with deep vein thrombosis. Central venous access is obtained through the internal jugular or femoral vein and a long sheath introduced through which the device is placed under fluoroscopy or ultrasound-guidance. The indications for and placement of inferior vena cava filters are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"       \"Placement of inferior vena cava filters and their complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary artery catheters &ndash; Pulmonary artery catheters are inserted through a venous sheath and the tip of the catheter is positioned in the pulmonary artery as a means to collect information on cardiac function (",
"      <a class=\"graphic graphic_figure graphicRef54333 \" href=\"mobipreview.htm?17/62/18415\">",
"       figure 3",
"      </a>",
"      ). Insertion of pulmonary artery catheters is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25221?source=see_link\">",
"       \"Insertion of pulmonary artery catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Pacemakers/Defibrillators",
"      </span>",
"      &ndash; The placement of",
"      <span class=\"nowrap\">",
"       pacemaker/defibrillator",
"      </span>",
"      leads also requires central venous access (",
"      <a class=\"graphic graphic_figure graphicRef67053 \" href=\"mobipreview.htm?16/32/16899\">",
"       figure 4",
"      </a>",
"      ). After the vein is accessed, a sheath is introduced through which the pacemaker leads are introduced and positioned into the heart. The leads are attached to the pacemaker, which is placed into a subcutaneous pocket similar to other subcutaneous port devices (see",
"      <a class=\"local\" href=\"#H362076162\">",
"       'Subcutaneous port'",
"      </a>",
"      above). Issues related to cardiac pacemakers and defibrillators are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link&amp;anchor=H6#H6\">",
"       \"Temporary cardiac pacing\", section on 'Insertion techniques'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103780\">",
"    <span class=\"h1\">",
"     DEVICE SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of central venous catheters and devices are available. Device selection depends primarily upon the indication for access but patient anatomy and other patient-related factors may also have a bearing.",
"   </p>",
"   <p>",
"    The choice between temporary (non-tunneled) versus permanent (tunneled, port) placement, depends upon the indication for central access. Patients who require access for only a short period of time (days) need not be exposed to the discomfort or risks associated with tunneled devices. Patients who need long-term access (weeks, permanent) benefit from tunneled or port devices, which are associated with lower rates of catheter infection compared with non-tunneled catheters. Selected patients may benefit from antibiotic-coated catheters based upon infectious risk, cost, and anticipated duration of the catheter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Type of catheter'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A single lumen, large-bore introducer sheath facilitates rapid administration of large volumes of fluid during emergencies. For less emergent fluid resuscitation, a non-tunneled central line is preferred over peripherally inserted central catheters (PICC), which do not provide adequate flow rates due to their small caliber and longer catheter length.",
"   </p>",
"   <p>",
"    Multiple lumen catheters are used more often than single lumen catheters, primarily because of the need to administer multiple pharmaceutical agents. In general, the smallest diameter catheter (fewer lumens) appropriate for the clinical situation should be used to reduce the risk of venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with port devices, tunneled catheters have some disadvantages. Tunneled catheters may have higher infection rates related to care of the external catheter (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, activities such as showering or swimming with tunnelled catheters are limited. Because subcutaneous ports allow more normal activities and cannot be seen (and thus are not an external reminder of the patient&rsquo;s illness), ports are often preferred when intermittent infusion therapy (eg, chemotherapy) is needed. The disadvantage of subcutaneous port devices is the need to puncture the port through the skin to access the device and the small caliber of the catheter, and thus, limited infusion rate. Port devices are not appropriate for patients who require frequent dosing or continuous infusion of larger fluid volumes such as with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103787\">",
"    <span class=\"h1\">",
"     SITE SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of the most appropriate site for central venous cannulation is based upon the expertise and skill of the operator, patient anatomy, the risks associated with placement (eg, coagulopathy, pulmonary disease), and access needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Although it is tempting to always use the same approach, knowledge of access techniques at multiple access sites is important to meet varying patient needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/14\">",
"     14",
"    </a>",
"    ]. Higher success rates and lower rates of mechanical complications are clearly related to more operator experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commonly used vein cannulation sites for central venous access include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jugular vein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      External jugular vein",
"     </li>",
"     <li>",
"      Internal jugular vein (central, posterior, anterior approaches)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subclavian vein (supraclavicular, infraclavicular, axillary approaches)",
"     </li>",
"     <li>",
"      Femoral vein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific techniques for placement of central venous catheters at these sites are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The needle insertion site should be chosen in an area that is not contaminated or will potentially become contaminated (eg, burned or infected skin, adjacent to tracheostomy or open surgical wound) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific anatomic sites and cannulation approaches have inherent advantages and disadvantages (",
"    <a class=\"graphic graphic_table graphicRef71716 \" href=\"mobipreview.htm?1/53/1885\">",
"     table 1",
"    </a>",
"    ). Access sites with altered local anatomy (eg, prior clavicle fracture), sites with multiple scars from prior access, and the presence of another central venous catheter or device, such as a pacemaker, or internal defibrillator, are associated with higher rates of access failure, malposition, dysrhythmia and other complications, and thus are avoided, if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/4,18,19\">",
"     4,18,19",
"    </a>",
"    ]. If a patient has significant unilateral lung disease, the hemithorax ipsilateral to the disease should be cannulated (internal jugular, subclavian access) to minimize respiratory decompensation in the event of a procedure-related pneumothorax. Subclavian venous access for hemodialysis catheters is avoided due to the risk of venous stenosis complicating subsequent hemodialysis access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link&amp;anchor=H79682271#H79682271\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\", section on 'Basic principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Right subclavian anatomy carries the theoretical advantage of lower pneumothorax risk due to the lower pleural apex and absence of the thoracic duct. However, this access site is associated with higher rates of catheter malposition and vessel trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382365678\">",
"    <span class=\"h2\">",
"     Subclavian versus internal jugular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews have identified one randomized trial comparing subclavian with internal jugular access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/1,21-23\">",
"     1,21-23",
"    </a>",
"    ]. There appears to be little variation in major mechanical complications between these sites. Observational studies suggest a preference for subclavian access for minimizing infection, but these results have not been validated in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/21\">",
"     21",
"    </a>",
"    ]. The randomized trial that compared internal jugular to subclavian port access for cancer therapy found no significant differences in infection rates or mechanical complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/23\">",
"     23",
"    </a>",
"    ]. Pulmonary complications such as hemothorax and pneumothorax appear equivalent despite historic and anecdotal reports of higher rates with the subclavian approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/1\">",
"     1",
"    </a>",
"    ]. However, for patients who are cachectic or have respiratory compromise, a jugular approach may be preferred. Arterial puncture may occur more frequently with the jugular approach, but recognition of bleeding and its control are easier at this site. The subclavian site is typically avoided in patients with coagulopathy, but there is little evidence to support this preference. (See",
"    <a class=\"local\" href=\"#H177530472\">",
"     'Coagulopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382365406\">",
"    <span class=\"h2\">",
"     Femoral access versus other sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews have identified two randomized trials comparing upper torso and femoral access sites finding no difference in mechanical catheter-related complications, but femoral access appears to be associated with higher rates of infection and iliofemoral thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/13,17,22,24-28\">",
"     13,17,22,24-28",
"    </a>",
"    ]. In the trial comparing femoral versus subclavian access, the risk of infectious complications was significantly increased for femoral access (relative risk [RR] 4.57, 95% CI, 1.95-10.71 for catheter colonization with or without sepsis; RR 3.65, 95% CI, 1.40-9.56 for catheter colonization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/17\">",
"     17",
"    </a>",
"    ]. In the other trial comparing femoral versus internal jugular access for hemodialysis, no significant differences in the rate of bacterial colonization or catheter-related bloodstream infection were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/28\">",
"     28",
"    </a>",
"    ]. However, rates of bacterial colonization varied depending upon body mass index with higher rates of colonization seen at internal jugular sites in low body mass index (BMI) patients (BMI &lt;24), and at femoral sites in high BMI patients (BMI &gt;28). Based upon these results, we generally avoid the femoral site in the absence of clinical factors such as severe coagulopathy, an uncooperative patient, or another alternative site, when the operator is sufficiently experienced with non-femoral central venous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/3\">",
"     3",
"    </a>",
"    ]. When used, femoral catheters should be removed as soon as possible to reduce catheter-associated complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3103794\">",
"    <span class=\"h2\">",
"     Emergency central access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achieving rapid intravenous access is essential during trauma and cardiopulmonary resuscitation (CPR). The most experienced operator available should perform central venous catheterization, when it is needed. Volume resuscitation does not generally require central access if sufficient peripheral intravenous access can be obtained (eg, 14 gauge or 16 gauge intravenous catheters). Peripheral intravenous catheterization is preferred due to the higher flow rates that can be achieved through these short, large-bore catheters. However, peripheral access may be challenging in the patient who is in shock. Under these circumstances, a single lumen, large bore central venous introducer sheath can be used. (See",
"    <a class=\"local\" href=\"#H3103759\">",
"     'Non-tunneled'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Femoral venous access is less likely to disrupt CPR, whereas subclavian or internal jugular insertion may interfere with chest compressions or intubation efforts. In a small, randomized study of patients receiving CPR, real-time ultrasound-guided femoral catheterization was faster and more likely to be successful than other approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Internal jugular access (especially right-sided) carries the lowest rate of catheter malposition and may be the optimal central venous access site in emergency situations when correct positioning is needed for immediate use, such as for drug administration or transvenous pacing (",
"    <a class=\"graphic graphic_table graphicRef71716 \" href=\"mobipreview.htm?1/53/1885\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. The supraclavicular approach to the subclavian vein is another option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/30\">",
"     30",
"    </a>",
"    ]. Instillation of medications via the subclavian or internal jugular veins allows rapid delivery to the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3104738\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-tunneled percutaneous central catheters are usually placed at the bedside, while tunneled catheters and port devices can be placed in an interventional suite or operating room using fluoroscopic guidance. The equipment needed for central venous catheterization is given in the table (",
"    <a class=\"graphic graphic_table graphicRef54646 \" href=\"mobipreview.htm?26/30/27115\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232389409\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent should be obtained for any central venous catheter including those placed percutaneously or requiring an incision (eg, port). Consent for vascular access is implied when treatment is sought during emergent situations.",
"   </p>",
"   <p>",
"    The procedure plan, including indications, benefits and potential complications of the procedure (eg, pneumothorax) should be discussed with the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    legal guardian. The potential need to perform a secondary procedure, such as chest tube placement to evacuate a pneumothorax, should also be conveyed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232389417\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be monitored during central venous access procedures, including continuous cardiac rhythm and pulse oximetry. Supplemental oxygen should be immediately available and, for some patients, it may be prudent to administer oxygen by nasal cannula prior to covering the patient&rsquo;s head with any drapes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232389424\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the access sites and approach are chosen, the patient is positioned to maximize comfort. While preparing and draping the patient, a supine position is adequate. The bed or table should be placed at a height that allows the operator to remain comfortable throughout the procedure. The patient is positioned to maximize the diameter of the vein during the vascular access procedure, which depends upon the site selected. Although Trendelenburg position facilitates venous filling for jugular and subclavian access and may reduce the risk of venous air embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/33-37\">",
"     33-37",
"    </a>",
"    ], critically ill and obese patients may not tolerate this position. Patients at risk for respiratory compromise may require anesthesia with a controlled airway to safely place a central catheter or device. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35482?source=see_link&amp;anchor=H708418#H708418\">",
"     \"Anesthesia for the obese patient undergoing non-cardiac surgery\", section on 'Positioning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232389432\">",
"    <span class=\"h2\">",
"     Site preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair should be clipped from the access site prior to skin preparation. Clipping is preferred to shaving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/38\">",
"     38",
"    </a>",
"    ]. We apply a chlorhexidine-based solution to the access site and allow it to dry prior to draping the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/2,39\">",
"     2,39",
"    </a>",
"    ]. When jugular or subclavian access is planned, preparing the skin of the neck and chest bilaterally facilitates access to alternative sites in the event the planned venous site cannot be cannulated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232389455\">",
"    <span class=\"h2\">",
"     Sterile technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce infectious complications, all central venous access procedures, including emergency procedures, should be performed in a location that permits the use of aseptic technique with full barrier precautions including sterile drapes large enough to cover the entire patient, surgical antiseptic hand wash, sterile gown, mask, gloves, and cap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/3,40,41\">",
"     3,40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Intravascular device placement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232389334\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient movement may preclude successful cannulation and, in a conscious patient, every effort should be taken to ensure patient comfort and cooperation. This is accomplished using sedation and local anesthesia (topical, infiltrated). For patients who are awake and anxious, minimal sedation can be achieved with a low dose, short-acting benzodiazepine to help the patient relax. Deeper sedation may be needed, especially in uncooperative children or adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical anesthetics are helpful and effective when time permits, particularly in children. The algorithm provides guidance regarding selection of an appropriate topical agent in children (",
"    <a class=\"graphic graphic_algorithm graphicRef67047 \" href=\"mobipreview.htm?35/56/36751\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infiltration of the skin overlying the access site is accomplished usually with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (eg, 1 or 2 percent). Lidocaine with epinephrine is generally unnecessary but may be useful during the placement of tunneled catheters to decrease bleeding from the subcutaneous tunnel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subcutaneous infiltration of local anesthetics may also be helpful but overzealous infiltration can distort landmarks, increase the depth of penetration needed to access the vessel, and can cause vein compression making needle access more difficult.",
"   </p>",
"   <p>",
"    Care should be taken not to inject air into the subcutaneous tissues, because it will interfere with the transmission of ultrasound waves. (See",
"    <a class=\"local\" href=\"#H177533298\">",
"     'Use of ultrasound'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    For tunneled catheters or port placement, infiltration of a longer acting local anesthetic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) into the tract or subcutaneous pocket will help to limit postoperative pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of postoperative pain\", section on 'Preemptive analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177533298\">",
"    <span class=\"h1\">",
"     USE OF ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the placement of central catheters, ultrasound imaging evaluates venous patency in patients who have a history of prior deep vein thrombosis in the region of the proposed access site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link&amp;anchor=H20#H20\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Duplex ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familiarity with ultrasound-guided access is a critical aspect for the practitioner performing frequent central venous catheterization. Static ultrasound can be helpful to localize the vein for access when using techniques that rely on knowledge of anatomic landmarks (ie, landmark technique), or alternatively dynamic ultrasound can used to guide the needle into the vein in real-time. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H18#H18\">",
"     \"Principles of ultrasound-guided venous access\", section on 'Dynamic ultrasound to guide vein cannulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H1232392861#H1232392861\">",
"     \"Principles of ultrasound-guided venous access\", section on 'Ultrasound-guided techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials have found that real-time ultrasound imaging during needle placement reduces time to venous cannulation and reduces the risk of complications for jugular and femoral access. Ultrasound guidance is recommended, whenever available, and is particularly useful in pediatric access and for high-risk patients such as those with coagulopathy. When ultrasound is not available, central catheters are placed using landmark techniques, but even experienced clinicians are encouraged to learn ultrasound-guided techniques. The principles of ultrasound and techniques to identify venous structures for venous access are discussed in detail elsewhere. (See",
"    <a class=\"local\" href=\"#H3104780\">",
"     'General technique'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Bedside ultrasound is also under investigation as an alternative modality to detect guidewire position and detect postprocedure pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. A metaanalysis pooled the results of 20 studies, finding a sensitivity of 88 percent and specificity of 99 percent, respectively, for the detection of pneumothorax using ultrasonography, and 52 and 100 percent, respectively, for chest radiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the accuracy of the diagnosis using ultrasound was dependent upon the skill of the ultrasound operator. (See",
"    <a class=\"local\" href=\"#H1232392311\">",
"     'Confirmation of catheter tip positioning'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26408?source=see_link\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3104780\">",
"    <span class=\"h1\">",
"     GENERAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The placement of central catheters and other venous devices follows similar principles. Specific details of central catheter placement for the various anatomic locations (jugular, subclavian, femoral), and other devices are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H177534136\">",
"     'Other devices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232392623\">",
"    <span class=\"h2\">",
"     Nontunnelled central catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general method for placing non-tunnelled central catheters is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain the equipment and devices needed for catheter placement (",
"      <a class=\"graphic graphic_picture graphicRef82032 \" href=\"mobipreview.htm?35/49/36625\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54646 \" href=\"mobipreview.htm?26/30/27115\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prepare (consent, sedation, antibiotics) and position the patient",
"     </li>",
"     <li>",
"      Using sterile technique, prepare the skin and drape the patient",
"     </li>",
"     <li>",
"      Identify the vein with ultrasound",
"     </li>",
"     <li>",
"      Infiltrate the skin with local anesthetic",
"     </li>",
"     <li>",
"      Cannulate the vein (needle or angiocatheter) using ultrasound guidance (preferred) and confirm the intravenous location of the needle",
"     </li>",
"     <li>",
"      Insert the guidewire into the vein through the access needle or angiocatheter",
"     </li>",
"     <li>",
"      Remove the needle or angiocatheter while controlling the guidewire",
"     </li>",
"     <li>",
"      Make a nick in the skin at the puncture site adjacent the guidewire with a scalpel",
"     </li>",
"     <li>",
"      Advance the dilator over the guidewire into the vein taking care to control the guidewire, then remove the dilator",
"     </li>",
"     <li>",
"      Thread the catheter over the guidewire, taking care to control the guidewire",
"     </li>",
"     <li>",
"      Remove the guidewire, taking care to control the catheter",
"     </li>",
"     <li>",
"      Sequentially aspirate blood from each access hub and flush with saline, to ensure functioning of the catheter",
"     </li>",
"     <li>",
"      Suture the catheter into place and dress the site using sterile technique",
"     </li>",
"     <li>",
"      Confirm the position of the tip of the catheter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177534136\">",
"    <span class=\"h2\">",
"     Other devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic principles for placing other central venous devices are similar to those outlined above; however, a venous sheath is typically placed over the guidewire into the vein first and the catheter, device, or pacemaker lead is introduced through it. Once the device is in place, the sheath is removed. A brief description of the placement of these devices compared with standard percutaneous central catheters is given below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177534183\">",
"    <span class=\"h3\">",
"     Venous sheath placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introducer sheath (eg, Cordis) is a combined dilator and sheath assembly with a side port for intravenous access. Once the guidewire is in place and the vessel is dilated, the dilator and sheath are advanced over the guidewire together and subsequently the dilator and guidewire are removed leaving the sheath in place. Once the sheath is in place, the side port is aspirated and irrigated to check function, and the sheath is sutured to the skin at its exit site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177534144\">",
"    <span class=\"h3\">",
"     Tunneled catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous access for tunneled catheters is obtained in a manner similar to non-tunneled catheters. The exit site of the catheter on the skin is chosen, which determines the length of catheter that will be needed for proper catheter tip positioning. For some tunneled catheters, the excess length of catheter provided is trimmed before the catheter is tunneled; for others, it can be trimmed afterward. Other types of catheters come in fixed lengths (eg, dialysis catheters) and the position of the exit site is chosen to accommodate the predetermined length of the catheter. For subclavian and jugular tunneled catheters, the exit site on the chest wall should be located below the midclavicle in a position that does not interfere with upper extremity mobility, or clothing.",
"   </p>",
"   <p>",
"    Percutaneous access is performed as outlined above. Once the guidewire is in position, the skin at the guidewire exit site is incised to accommodate at least the diameter of the catheter. Following administration of local anesthesia to the catheter exit site and planned subcutaneous tunnel, an incision is made at the planned catheter exit site. A tunnelling device is usually included in the catheter kit, and it is attached to the end-hole of the catheter. The catheter is advanced subcutaneously from the catheter exit site to the guidewire exit site, and the tunneler is removed. Care is taken to ensure that the tunnel provides a gentle curve in the catheter from the catheter exit site to the guidewire site. Acute angulation may lead to poor flow rates and catheter malfunction. After dilating the vein, the",
"    <span class=\"nowrap\">",
"     dilator/sheath",
"    </span>",
"    combination is placed over the wire. The dilator is removed and the catheter is advanced through the sheath and the sheath peeled away. The position of the tip of the catheter is checked and adjusted, as needed. The cuff of the tunneled catheter is ideally located at the exit site of the catheter, but it may come to rest more cranially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177534152\">",
"    <span class=\"h3\">",
"     Subcutaneous ports",
"    </span>",
"    &nbsp;&mdash;&nbsp;For subcutaneous port placement, a pocket is created for the port device after venous access has been established. Prior to placing the port, the function should be checked by inserting a needle and irrigating with saline, which should flow freely through the port hub.",
"   </p>",
"   <p>",
"    Once the guidewire is in place, local anesthetic is administered into the skin and subcutaneous tissue of the planned pocket. An incision is made through the skin and subcutaneous tissues. With electrocautery, a pocket is created to accommodate the device by undermining the subcutaneous tissue. The device is placed into the pocket, and the size of the pocket and orientation of the device adjusted, as needed.",
"   </p>",
"   <p>",
"    Once the pocket is completed, the catheter is tunneled from the pocket to the guidewire exit site, if needed (eg, jugular venous access). Care is taken to avoid catheter angulation which will lead to mechanical dysfunction. After dilating the vein, the",
"    <span class=\"nowrap\">",
"     dilator/sheath",
"    </span>",
"    combination is placed over the wire. The dilator is removed and the catheter is placed through the sheath, and the sheath peeled away. The catheter is positioned and adjusted as needed. The excess catheter is trimmed and attached to the hub of the port device, which is placed into the pocket and sutured into place. Placing sutures in at least three points of fixation into fascial tissue is important to prevent port rotation, which can transpose the access hub away from the skin surface making access impossible. The subcutaneous tissues and skin are sutured closed. Prior to dressing the wound, the port should be accessed through the skin, and the port aspirated and irrigated to confirm its proper functioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1232392311\">",
"    <span class=\"h1\">",
"     CONFIRMATION OF CATHETER TIP POSITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of catheter tip positioning can use one or more of the following methods: chest radiography, ultrasound, fluoroscopy, and transesophageal echocardiography (typically intraoperative) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/42-51\">",
"     42-51",
"    </a>",
"    ]. Chest radiography and fluoroscopy are the most commonly used methods. The use of ultrasound is discussed above. (See",
"    <a class=\"local\" href=\"#H177533298\">",
"     'Use of ultrasound'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We obtain a postprocedure chest radiograph to confirm the course of the catheter and position of the tip prior to using jugular and subclavian catheters in non-life-threatening situations. Femoral catheters do not generally require radiologic confirmation of position, and some clinicians have questioned the need for routine radiography for uncomplicated right internal jugular catheters placed with a single needle pass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/46,48,49\">",
"     46,48,49",
"    </a>",
"    ]. The optimal positioning of the tip of the catheter depends on the specific access site. In general, catheters function well with the tip situated in any major vein. However, suboptimal tip position may be related to delayed complications. If a catheter is malpositioned within the venous system, it may still be used for fluid administration under emergency circumstances but should be repositioned as soon as feasible. In contrast, inadvertent placement of a catheter into the arterial system mandates surgical consultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44553/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter tip confirmation and positioning, and management of malpositioned catheters and inadvertent arterial puncture are discussed separately for the commonly used access sites (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=see_link&amp;anchor=H86783685#H86783685\">",
"     \"Placement of jugular venous catheters\", section on 'Catheter placement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36024?source=see_link&amp;anchor=H662983898#H662983898\">",
"     \"Placement of femoral venous catheters\", section on 'Confirmation of femoral catheter position'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=see_link&amp;anchor=H662982527#H662982527\">",
"     \"Placement of subclavian venous catheters\", section on 'Confirmation of subclavian catheter position'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272976359\">",
"    <span class=\"h1\">",
"     CATHETER MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of central catheters is aimed at preventing catheter infection and thrombosis, and handling mechanical complications.",
"   </p>",
"   <p>",
"    Proper catheter maintenance involves minimizing the duration of temporary catheter access, performing routine catheter site inspections, periodically changing the catheter site dressing, using aseptic technique when handling catheters, and changing the catheter, when indicated. Catheter site management and catheter care are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Site care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Catheter care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheter-related thrombosis may be reduced using catheter lock solutions, and when thrombosis occurs, thrombolytic therapy may restore lumen patency, but thrombosis related to mechanical problems usually requires replacement of the catheter. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2121?source=see_link&amp;anchor=H21997797#H21997797\">",
"     \"Antibiotic lock therapy for treatment of catheter-related bloodstream infections\", section on 'Anticoagulant'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link&amp;anchor=H32#H32\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Thrombosis prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link&amp;anchor=H29#H29\">",
"     \"Catheter-induced upper extremity venous thrombosis\", section on 'Catheter management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3105206\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications related to central venous access (",
"    <a class=\"graphic graphic_table graphicRef77376 \" href=\"mobipreview.htm?11/30/11755\">",
"     table 3",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36024?source=see_link\">",
"     \"Placement of femoral venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177530200\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common indications for central venous access include insertion of central venous catheters for administration of medications or fluid, hemodynamic monitoring, plasmapheresis, apheresis, hemodialysis, and continuous renal replacement therapy. In addition, central venous access may be necessary in patients with poor peripheral venous access. Central venous access is also used to place other venous devices, including inferior vena cava filters, pacemakers, defibrillators, and to perform venous interventions. (See",
"      <a class=\"local\" href=\"#H3103243\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coagulopathy is a relative contraindication to central venous catheterization, with thrombocytopenia posing a greater risk than prolonged clotting time. A subclavian approach should generally be avoided in patients at risk for bleeding due to an inability to effectively monitor or compress the venipuncture site. If central access is absolutely necessary, the most experienced individual available should perform the procedure. (See",
"      <a class=\"local\" href=\"#H177530472\">",
"       'Coagulopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Central venous catheters can be inserted through the jugular, subclavian, or femoral veins or via upper arm peripheral veins. The type of catheter and site chosen are often determined by the clinical scenario of the individual patient and provider preference. The optimal site is determined by operator experience, patient anatomy, and clinical circumstances. (See",
"      <a class=\"local\" href=\"#H3103787\">",
"       'Site selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the placement of central catheters, we use ultrasound imaging to evaluate venous patency in patients who have a history of prior deep vein thrombosis in the region of the proposed access site. (See",
"      <a class=\"local\" href=\"#H177533298\">",
"       'Use of ultrasound'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=see_link\">",
"       \"Catheter-induced upper extremity venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of real-time ultrasound imaging during needle placement reduces time to venous cannulation and reduces the risk of complications. Thus, ultrasound guidance is recommended, when equipment and expertise are available, and is particularly useful in pediatric venous access and in high-risk patients, such as those with coagulopathy (See",
"      <a class=\"local\" href=\"#H177533298\">",
"       'Use of ultrasound'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H26#H26\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central venous catheterization is performed through a series of well-defined steps. Venous sheaths are placed in a similar manner and can be used for intravenous infusion or for the placement of other devices such as tunneled catheters, subcutaneous ports, pulmonary artery catheters, pacemaker leads, inferior vena cava filters, and venous stents. (See",
"      <a class=\"local\" href=\"#H3104780\">",
"       'General technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We obtain a chest radiograph following jugular and subclavian catheter placement to confirm the position of the catheter tip. Femoral catheters do not generally require radiological confirmation of position. The need to confirm placement in all patients undergoing jugular venous access procedures is controversial. Bedside ultrasound is under investigation as an alternative modality to detect pneumothorax. (See",
"      <a class=\"local\" href=\"#H1232392311\">",
"       'Confirmation of catheter tip positioning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/1\">",
"      Ruesch S, Walder B, Tram&egrave;r MR. Complications of central venous catheters: internal jugular versus subclavian access--a systematic review. Crit Care Med 2002; 30:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/2\">",
"      McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/3\">",
"      American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM, Apfelbaum JL, et al. Practice guidelines for central venous access: a report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology 2012; 116:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/4\">",
"      Polderman KH, Girbes AJ. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med 2002; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/5\">",
"      Dryden MS, Samson A, Ludlam HA, et al. Infective complications associated with the use of the Quinton 'Permcath' for long-term central vascular access in haemodialysis. J Hosp Infect 1991; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/6\">",
"      Niederhuber JE, Ensminger W, Gyves JW, et al. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 1982; 92:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/7\">",
"      Gyves J, Ensminger W, Niederhuber J, et al. Totally implanted system for intravenous chemotherapy in patients with cancer. Am J Med 1982; 73:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/8\">",
"      Barbetakis N, Asteriou C, Kleontas A, Tsilikas C. Totally implantable central venous access ports. Analysis of 700 cases. J Surg Oncol 2011; 104:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/9\">",
"      Knebel P, Lopez-Benitez R, Fischer L, et al. Insertion of totally implantable venous access devices: an expertise-based, randomized, controlled trial (NCT00600444). Ann Surg 2011; 253:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/10\">",
"      Pegues D, Axelrod P, McClarren C, et al. Comparison of infections in Hickman and implanted port catheters in adult solid tumor patients. J Surg Oncol 1992; 49:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/11\">",
"      Plumhans C, Mahnken AH, Ocklenburg C, et al. Jugular versus subclavian totally implantable access ports: catheter position, complications and intrainterventional pain perception. Eur J Radiol 2011; 79:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/12\">",
"      Timsit JF. Central venous access in intensive care unit patients: is the subclavian vein the royal route? Intensive Care Med 2002; 28:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/13\">",
"      Marik PE, Flemmer M, Harrison W. The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: a systematic review of the literature and meta-analysis. Crit Care Med 2012; 40:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/14\">",
"      Sterner S, Plummer DW, Clinton J, Ruiz E. A comparison of the supraclavicular approach and the infraclavicular approach for subclavian vein catheterization. Ann Emerg Med 1986; 15:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/15\">",
"      Sznajder JI, Zveibil FR, Bitterman H, et al. Central vein catheterization. Failure and complication rates by three percutaneous approaches. Arch Intern Med 1986; 146:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/16\">",
"      Arrighi DA, Farnell MB, Mucha P Jr, et al. Prospective, randomized trial of rapid venous access for patients in hypovolemic shock. Ann Emerg Med 1989; 18:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/17\">",
"      Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/18\">",
"      Mansfield PF, Hohn DC, Fornage BD, et al. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994; 331:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/19\">",
"      Reeves ST, Roy RC, Dorman BH, et al. The incidence of complications after the double-catheter technique for cannulation of the right internal jugular vein in a university teaching hospital. Anesth Analg 1995; 81:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/20\">",
"      The clinical anatomy of several invasive procedures. American Association of Clinical Anatomists, Educational Affairs Committee. Clin Anat 1999; 12:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/21\">",
"      Lorente L, Henry C, Mart&iacute;n MM, et al. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Crit Care 2005; 9:R631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/22\">",
"      Hamilton HC, Foxcroft DR. Central venous access sites for the prevention of venous thrombosis, stenosis and infection in patients requiring long-term intravenous therapy. Cochrane Database Syst Rev 2007; :CD004084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/23\">",
"      Biffi R, Orsi F, Pozzi S, et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol 2009; 20:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/24\">",
"      Parienti JJ, Thirion M, M&eacute;garbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 2008; 299:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/25\">",
"      Joynt GM, Kew J, Gomersall CD, et al. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest 2000; 117:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/26\">",
"      Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Crit Care Med 1995; 23:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/27\">",
"      Parienti JJ, du Cheyron D, Timsit JF, et al. Meta-analysis of subclavian insertion and nontunneled central venous catheter-associated infection risk reduction in critically ill adults. Crit Care Med 2012; 40:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/28\">",
"      Parienti JJ, Thirion M, M&eacute;garbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 2008; 299:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/29\">",
"      Hilty WM, Hudson PA, Levitt MA, Hall JB. Real-time ultrasound-guided femoral vein catheterization during cardiopulmonary resuscitation. Ann Emerg Med 1997; 29:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/30\">",
"      Dronen S, Thompson B, Nowak R, Tomlanovich M. Subclavian vein catheterization during cardiopulmonary resuscitation. A prospective comparison of the supraclavicular and infraclavicular percutaneous approaches. JAMA 1982; 247:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/31\">",
"      Kaye W, Bircher NG. Access for drug administration during cardiopulmonary resuscitation. Crit Care Med 1988; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/32\">",
"      Emerman CL, Bellon EM, Lukens TW, et al. A prospective study of femoral versus subclavian vein catheterization during cardiac arrest. Ann Emerg Med 1990; 19:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/33\">",
"      Ely EW, Hite RD, Baker AM, et al. Venous air embolism from central venous catheterization: a need for increased physician awareness. Crit Care Med 1999; 27:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/34\">",
"      Mirski MA, Lele AV, Fitzsimmons L, Toung TJ. Diagnosis and treatment of vascular air embolism. Anesthesiology 2007; 106:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/35\">",
"      Bellazzini MA, Rankin PM, Gangnon RE, Bjoernsen LP. Ultrasound validation of maneuvers to increase internal jugular vein cross-sectional area and decrease compressibility. Am J Emerg Med 2009; 27:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/36\">",
"      Samy Modeliar S, Sevestre MA, de Cagny B, Slama M. Ultrasound evaluation of central veinsin the intensive care unit:effects of dynamic manoeuvres. Intensive Care Med 2008; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/37\">",
"      Parry G. Trendelenburg position, head elevation and a midline position optimize right internal jugular vein diameter. Can J Anaesth 2004; 51:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/38\">",
"      Tanner J, Moncaster K, Woodings D. Preoperative hair removal: a systematic review. J Perioper Pract 2007; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/39\">",
"      Mimoz O, Pieroni L, Lawrence C, et al. Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients. Crit Care Med 1996; 24:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/40\">",
"      Geffers C, Meyer E. No reason to conclude that maximal sterile barrier precautions do not reduce catheter-related blood stream infections. Ann Surg 2011; 253:212.",
"     </a>",
"    </li>",
"    <li>",
"     Kost, SI. Ultrasound-assisted venous access. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King, C, Henretig, FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2008. p.1255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/42\">",
"      Palevsky HI. The early diagnosis of pulmonary arterial hypertension: can we do better? Chest 2011; 140:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/43\">",
"      Gillman LM, Blaivas M, Lord J, et al. Ultrasound confirmation of guidewire position may eliminate accidental arterial dilatation during central venous cannulation. Scand J Trauma Resusc Emerg Med 2010; 18:39.",
"     </a>",
"    </li>",
"    <li>",
"     Gu X, Paulsen W, Tisnado J, He Y, Li Z, Nixon JV: Malposition of a central venous catheter in the right main pulmonary artery detected by transesophageal echocardiography. J Am Soc Echocardiogr 2009; 22:1420",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/45\">",
"      Sawchuk C, Fayad A. Confirmation of internal jugular guide wire position utilizing transesophageal echocardiography. Can J Anaesth 2001; 48:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/46\">",
"      Lucey B, Varghese JC, Haslam P, Lee MJ. Routine chest radiographs after central line insertion: mandatory postprocedural evaluation or unnecessary waste of resources? Cardiovasc Intervent Radiol 1999; 22:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/47\">",
"      Gebhard RE, Szmuk P, Pivalizza EG, et al. The accuracy of electrocardiogram-controlled central line placement. Anesth Analg 2007; 104:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/48\">",
"      Abood GJ, Davis KA, Esposito TJ, et al. Comparison of routine chest radiograph versus clinician judgment to determine adequate central line placement in critically ill patients. J Trauma 2007; 63:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/49\">",
"      Lessnau KD. Is chest radiography necessary after uncomplicated insertion of a triple-lumen catheter in the right internal jugular vein, using the anterior approach? Chest 2005; 127:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/50\">",
"      Wirsing M, Schummer C, Neumann R, et al. Is traditional reading of the bedside chest radiograph appropriate to detect intraatrial central venous catheter position? Chest 2008; 134:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/51\">",
"      Francis KR, Picard DL, Fajardo MA, Pizzi WF. Avoiding complications and decreasing costs of central venous catheter placement utilizing electrocardiographic guidance. Surg Gynecol Obstet 1992; 175:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44553/abstract/52\">",
"      Guilbert MC, Elkouri S, Bracco D, et al. Arterial trauma during central venous catheter insertion: Case series, review and proposed algorithm. J Vasc Surg 2008; 48:918.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8194 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44553=[""].join("\n");
var outline_f43_32_44553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H177530200\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3103243\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177530472\">",
"      Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3103752\">",
"      CENTRAL CATHETERS AND DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3103759\">",
"      Non-tunneled",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3103766\">",
"      Implanted",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362076169\">",
"      - Tunneled",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H362076162\">",
"      - Subcutaneous port",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3103773\">",
"      Specialized venous devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3103780\">",
"      DEVICE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3103787\">",
"      SITE SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1382365678\">",
"      Subclavian versus internal jugular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1382365406\">",
"      Femoral access versus other sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3103794\">",
"      Emergency central access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3104738\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232389409\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232389417\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232389424\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232389432\">",
"      Site preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232389455\">",
"      Sterile technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232389334\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177533298\">",
"      USE OF ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3104780\">",
"      GENERAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1232392623\">",
"      Nontunnelled central catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177534136\">",
"      Other devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177534183\">",
"      - Venous sheath placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177534144\">",
"      - Tunneled catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177534152\">",
"      - Subcutaneous ports",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1232392311\">",
"      CONFIRMATION OF CATHETER TIP POSITIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272976359\">",
"      CATHETER MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3105206\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177530200\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8194|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?35/56/36751\" title=\"algorithm 1\">",
"      Topical pain control in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8194|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/3/18480\" title=\"figure 1\">",
"      Anterior view superficial veins of the upper extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/48/4868\" title=\"figure 2\">",
"      Vena cava filter models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/62/18415\" title=\"figure 3\">",
"      Insertion of Swan Ganz catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/32/16899\" title=\"figure 4\">",
"      ICD PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8194|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/49/36625\" title=\"picture 1\">",
"      Access needles and guidewire",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8194|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/53/1885\" title=\"table 1\">",
"      Advantages and disadvantages of central vein approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/30/27115\" title=\"table 2\">",
"      Central line equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/30/11755\" title=\"table 3\">",
"      Complications of central venous catheterization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35482?source=related_link\">",
"      Anesthesia for the obese patient undergoing non-cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/4/2121?source=related_link\">",
"      Antibiotic lock therapy for treatment of catheter-related bloodstream infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19385?source=related_link\">",
"      Evaluation and management of thrombocytopenia by primary care physicians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25221?source=related_link\">",
"      Insertion of pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36024?source=related_link\">",
"      Placement of femoral venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=related_link\">",
"      Placement of jugular venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=related_link\">",
"      Placement of subclavian venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26408?source=related_link\">",
"      Thoracic ultrasound: Indications, advantages, and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_32_44554="Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials";
var content_f43_32_44554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44554/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44554/contributors\">",
"     Jeffrey W Clark, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44554/contributors\">",
"     Axel Grothey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44554/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44554/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/32/44554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/32/44554/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/32/44554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with metastatic colon or rectal cancer cannot be cured, although a subset with liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lung-isolated disease are potentially curable with surgery. For other patients with metastatic colorectal cancer (mCRC), treatment is palliative and generally consists of systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For decades, 5-fluorouracil (5-FU) was the sole active agent. This has changed markedly since the year 2000, with the approval of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , three humanized monoclonal antibodies (MoAbs) that target vascular endothelial growth factor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) and the epidermal growth factor receptor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    ), intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , a recombinant fusion protein consisting of vascular endothelial growth factor (VEGF) binding portions from the human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    , an orally active inhibitor of angiogenic tyrosine kinases (including the VEGF receptors 1,2, and 3), as well as several other membrane-bound and intracellular kinases that are involved in normal cellular function and in pathologic processes. The best way to combine and sequence these agents is still not established.",
"   </p>",
"   <p>",
"    This topic review will cover the data from clinical trials evaluating systemic chemotherapy for nonresectable mCRC. General principles of treatment, and specific treatment recommendations, including the use of biomarkers to select therapy and a compilation of treatment protocols, are presented elsewhere, as is the use of systemic therapy for the purpose of downstaging potentially resectable CRC liver metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Therapy after resection of liver metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FLUOROPYRIMIDINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoropyrimidines such as 5-FU have been used for mCRC for over 40 years. The primary mechanism of cytotoxicity is thought to be impaired DNA synthesis via inhibition of thymidylate synthase (TS). Inhibition of RNA synthesis may further contribute to cytotoxicity of bolus regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    5-FU is rapidly metabolized to inactive compounds. Interpatient variation in the activity of the critical metabolizing enzyme dihydropyrimidine dehydrogenase (DPD) may account for toxicity differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/2\">",
"     2",
"    </a>",
"    ]. Individuals who lack DPD develop severe, potentially fatal side effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bolus 5-FU monotherapy has limited activity; only 10 percent achieve an objective response. Higher response rates can be achieved with infusional regimens, but the survival impact is minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The toxicity profile differs with bolus and infusional 5-FU. While rates of GI toxicity are similar, grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    neutropenia is more common with bolus 5-FU (31 versus 4 percent), while hand-foot syndrome is more frequent with infusional regimens (34 versus 13 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Leucovorin plus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    (LV) enhances 5-FU cytotoxicity by interacting with thymidylate synthase to form a stable ternary complex, prolonging inhibition of the enzyme by 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared to bolus 5-FU alone,",
"    <span class=\"nowrap\">",
"     FU/LV",
"    </span>",
"    is associated with a twofold higher response rate (21 versus 11 percent in two meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]), which, in one, translated into a small but statistically significant 10 percent improvement in one-year survival (47 versus 37 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/7\">",
"     7",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Until the development of combination regimens of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    was the standard first-line therapy for mCRC; it is still used in patients who cannot tolerate these triple drug regimens (see below).",
"   </p>",
"   <p>",
"    Most American patients receive a racemic mixture of d,l-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    . However, the l-isomer is the biologically active moiety, and a preparation of l-leucovorin is now commercially available in the US (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     LEVOleucovorin",
"    </a>",
"    , Fusilev). It is dosed at one-half that of d,l-leucovorin (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ), and is similarly effective as the racemic mixture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Optimizing the schedule and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several dose and schedules of 5-FU and LV are in clinical use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bolus regimens &mdash; There are two widely used bolus regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Mayo regimen: 5-FU (425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus low-dose LV (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      both given on days 1 to 5, every four to five weeks. A modification consists of 5-FU (370",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus high-dose LV (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      each given on days 1 to 5, every four to five weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The RPMI regimen: weekly 5-FU (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus LV (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      for six of every eight weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/11\">",
"       11",
"      </a>",
"      ]. The initial RPMI regimen, containing 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      5-FU weekly, was too toxic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least three trials have directly compared both approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/11,13,14\">",
"     11,13,14",
"    </a>",
"    ]. The monthly schedule causes more neutropenia and stomatitis, while the weekly schedule causes more diarrhea. Furthermore, five-day bolus regimen appears to be more toxic in women than in men. Given the lower rates of neutropenia and stomatitis and the ability to stop or modify therapy if toxicity occurs, the weekly RPMI regimen is generally preferred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The equivalence of low-dose (ie, 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose) versus high-dose (ie, 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose) LV for the weekly schedule has not yet been firmly established, although at least one trial suggests similar outcomes and a more favorable toxicity profile for the lower dose regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/11\">",
"     11",
"    </a>",
"    ]. Many clinicians use the lower dose regimen because of cost issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short-term infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      &mdash; Response rates with",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      have been further improved by the use of short-term infusional schedules of 5-FU. This was demonstrated in a trial of 448 patients who were randomly assigned to a monthly regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus bolus 5-FU (425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      on days 1 to 5 every four weeks or a bimonthly regimen (the de Gramont regimen, (",
"      <a class=\"graphic graphic_table graphicRef65525 \" href=\"mobipreview.htm?36/17/37149\">",
"       table 2",
"      </a>",
"      )) of leucovorin (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over two hours) followed by bolus 5-FU (400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and a 22-hour infusion of 5-FU (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       );",
"      </span>",
"      both drugs are given daily for two consecutive days every two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/16\">",
"       16",
"      </a>",
"      ]. The infusional regimen was associated with a significantly better response rate (33 versus 14 percent) and median PFS (28 versus 22 weeks), and a trend toward longer median survival (62 versus 57 weeks, p = 0.067).",
"      <br/>",
"      <br/>",
"      Infusional therapy also caused less hematologic and GI toxicity. For these reasons, the majority of regimens incorporating 5-FU into",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based regimens now use short-term infusional schedules.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chronomodulated 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronomodulation, a method where drug administration varies over a 24-hour period, is based upon the following principles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug absorption, transport, metabolism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elimination usually show diurnal changes.",
"     </li>",
"     <li>",
"      Most cellular detoxification rhythms appear to be coupled to the rest-activity cycle.",
"     </li>",
"     <li>",
"      These variations in target cell exposure to drugs and the diurnal rhythms that modulate cellular detoxification functions may impact the pharmacology of administered drugs, including 5-FU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronomodulated administration schedules of 5-FU with or without LV generally improve response rates and lessen toxicity as compared to nonchronomodulated schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. However, the true value of this approach has not been fully established, and it remains experimental. Chronomodulated scheduling of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimens is discussed below (see",
"    <a class=\"local\" href=\"#H40\">",
"     'Chronomodulated schedules'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Orally active fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orally active 5-FU analogs provide response rates that are comparable to IV",
"    <span class=\"nowrap\">",
"     5-FU/LV,",
"    </span>",
"    with the convenience of oral delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The available agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (Xeloda&reg;) and ftorafur (tegafur) plus uracil (UFT&reg;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is a fluoropyrimidine carbamate that is absorbed intact through the intestinal wall and then converted to 5-FU in three sequential enzymatic reactions. The final requisite enzyme, thymidine phosphorylase, is present at consistently higher levels in tumor compared to normal tissue, thereby providing the basis for enhanced selectivity for tumor cells and better tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two identically designed randomized trials (602 and 605 patients, respectively) have shown similar efficacy for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days) compared to IV",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (the Mayo regimen, see above) for the first-line treatment of mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    was associated with a modestly but significantly higher response rate than",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (25 versus 16 percent), but similar median time to tumor progression (TTP, 4.3 versus 4.7 months) and overall survival (12.5 versus 13.3 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/23\">",
"     23",
"    </a>",
"    ]. The incidence of grade 3 or 4 diarrhea, stomatitis, nausea, and neutropenic sepsis were significantly less in the capecitabine group; only hyperbilirubinemia and hand-foot syndrome were more common compared to",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"   </p>",
"   <p>",
"    In contrast to these data, objective response rates with second-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy are quite low in patients with",
"    <span class=\"nowrap\">",
"     5-FU/LV-refractory",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Capecitabine alone is an inappropriate treatment strategy for patients who have failed 5-FU-based regimens.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is approved in the US for first-line treatment of mCRC, when fluoropyrimidines alone are indicated. The approved dose is 1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days. Some have suggested that lower doses (beginning at 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days) improve the therapeutic index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/27\">",
"     27",
"    </a>",
"    ]. However, randomized trials have not established the comparative efficacy of these lower capecitabine doses. In at least one study using 1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily in 51 elderly patients with advanced CRC, treatment was well tolerated, and only six (12 percent) experienced grade 3 or 4 adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that the incidence and severity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    -associated toxicity are substantially higher when it is given after",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/29\">",
"     29",
"    </a>",
"    ]. The mechanism underlying this sequence-specific exacerbation of toxicity is unclear. The potential for excess toxicity is a consideration for patients who are being considered for crossover from",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    to capecitabine. However, this information is based on a relatively small number of patients and needs confirmation.",
"   </p>",
"   <p>",
"    Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    are discussed below, and hand-foot syndrome due to capecitabine is discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Irinotecan plus capecitabine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H33\">",
"     'Capecitabine plus oxaliplatin'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     UFT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UFT is a 4:1 molar combination of ftorafur with uracil, which competitively inhibits the degradation of 5-FU, resulting in sustained plasma and intratumoral concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/20\">",
"     20",
"    </a>",
"    ]. Response rates are approximately 25 percent with UFT monotherapy and 40 percent in combination with oral LV (150 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/30\">",
"     30",
"    </a>",
"    ]. In phase III studies, UFT plus LV has comparable efficacy and better tolerability as compared to IV bolus 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The dose limiting toxicity is diarrhea. Myelosuppression and hand-foot syndrome are infrequent. UFT is not available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Raltitrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21525?source=see_link\">",
"     Raltitrexed",
"    </a>",
"    (Tomudex), a folate analog, is a pure thymidylate synthase inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/33\">",
"     33",
"    </a>",
"    ]. It is not more active than 5-FU and is not approved in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In at least one randomized trial that assigned 905 patients with MCRC to raltitrexed, infusional 5-FU, or bolus plus short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (the de Gramont regimen), raltitrexed was associated with the greatest toxicity and worst health-related quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21525?source=see_link\">",
"     Raltitrexed",
"    </a>",
"    , which is not available in the US, may be a useful substitute for 5-FU in patients with dihydropyrimidine dehydrogenase deficiency (which markedly increases 5-FU toxicity), or possibly as a component of second-line therapy in patients failing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until the development of combination regimens of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV)-modulated 5-FU with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    was the standard first-line therapy for mCRC, and it is still used in patients who cannot tolerate these triple drug regimens. If it is to be used alone, because of the more favorable toxicity profile, we recommend short duration infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (ie, the de Gramont regimen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/16\">",
"     16",
"    </a>",
"    ] rather than the Mayo regimen of treatment for five consecutive days once per month. An acceptable alternative is weekly 5-FU (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus LV (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    for six of every eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    is a more convenient (but not necessarily less toxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/41\">",
"     41",
"    </a>",
"    ]) alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU in clinical settings where fluoropyrimidines alone are indicated (ie, in patients who are not considered appropriate candidates for intensive therapy using a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based combination regimen). The approved dose is 1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days, although most US oncologists begin at a lower dose (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     IRINOTECAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    , a topoisomerase I inhibitor, is active as monotherapy in advanced CRC; it is more active in combination with 5-FU as well as with the targeted agents",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Irinotecan alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a single agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    has demonstrated clinical benefit after 5-FU failure in patients with mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/42,44-46\">",
"     42,44-46",
"    </a>",
"    ]. This was illustrated in a trial of 189 patients with 5-FU-refractory disease who were randomly assigned to best supportive care with or without irinotecan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/44\">",
"     44",
"    </a>",
"    ]. The irinotecan group had superior one-year survival (36 versus 14 percent) and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different administration schedules (weekly, every two, or every three weeks) appear to result in similar therapeutic outcomes, although in one report, the every three-week schedule was associated with significantly less grade 3 diarrhea (36 versus 19 percent) than a weekly regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/47\">",
"     47",
"    </a>",
"    ]. Diarrhea is the dose-limiting side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and may be severe; early use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    decreases its severity and is essential to prevent treatment-related mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Irinotecan plus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three pivotal phase III trials demonstrated a survival benefit for combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    compared to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a European trial, 387 previously untreated patients were randomly assigned to",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/48\">",
"       48",
"      </a>",
"      ]. Triple therapy could be administered either weekly (irinotecan 80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      5-FU 2300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours, LV 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      or every other week (irinotecan 180",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1, 5-FU 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      bolus followed by 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 22 hours, both on days 1 and 2, and LV 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 2 [the Douillard FOLFIRI regimen], (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      )). The control arm allowed weekly (5-FU 2600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours plus LV 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      or every other week regimens (5-FU 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      bolus followed by 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 22 hours, both on days 1 and 2, and LV 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 2).",
"      <br/>",
"      <br/>",
"      Triple therapy was associated with a significantly higher response rate (49 versus 31 percent), as well as longer TTP (6.7 versus 4.4 months) and median survival (17.4 versus 14.1 months). Although some toxicities were more common with irinotecan (ie, grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      diarrhea [44 versus 27 percent] and neutropenia [29 versus 2 to 4 percent]), they were manageable, reversible, and noncumulative.",
"     </li>",
"     <li>",
"      Nearly identical results were found in another European trial comparing weekly infusional",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      with and without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      in 430 patients with mCRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/50\">",
"       50",
"      </a>",
"      ]. As with the prior trial, the addition irinotecan was associated with significantly higher response rates and progression-free survival, but the difference in median survival (20.1 versus 16.9 months) did not reach the level of statistical significance.",
"     </li>",
"     <li>",
"      In contrast to the European trials, American studies focused on more convenient triple combination regimens that include bolus",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (eg, the Saltz regimen or IFL). Although the benefit of IFL over",
"      <span class=\"nowrap\">",
"       5-FU/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"        leucovorin",
"       </a>",
"      </span>",
"      was shown in an American randomized trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/49\">",
"       49",
"      </a>",
"      ], the IFL regimen causes more toxicity than infusion 5-FU-based regimens such as FOLFIRI (",
"      <a class=\"graphic graphic_table graphicRef76300 \" href=\"mobipreview.htm?19/2/19502\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/49,51-55\">",
"       49,51-55",
"      </a>",
"      ]. As a result, bolus 5-FU-based",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      combinations such as IFL should no longer be considered an appropriate choice for",
"      <span class=\"nowrap\">",
"       irinotecan/5-FU/LV",
"      </span>",
"      therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H12#H12\">",
"       \"Enterotoxicity of chemotherapeutic agents\", section on 'Irinotecan plus 5-FU'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"       \"Treatment protocols for colorectal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Drug sequence and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug sequencing and method of administration influence toxicity. As noted above, infusional 5-FU-based",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    regimens (eg, FOLFIRI, including the originally published Douillard regimen) (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) appear to be associated with less GI toxicity than bolus 5-FU-based regimens such as IFL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, in one report, the area under the concentration x time curve (AUC) for the irinotecan metabolite SN-38 was 40 percent lower when irinotecan preceded 5-FU, and this sequence of administration was associated with fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pharmacokinetic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major issue with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    is the marked interpatient variability in pharmacodynamics and pharmacokinetics that correlates poorly with body surface area-based dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Pharmacokinetic variability has been related to biliary excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Even modest elevations in serum bilirubin increase the risk for severe neutropenia and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/61\">",
"     61",
"    </a>",
"    ]. Lower starting doses are appropriate in such patients, particularly those receiving weekly therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H40#H40\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Irinotecan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacokinetic variability has also been linked to inherited alterations in the hepatic metabolic pathways that control",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    disposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/64\">",
"     64",
"    </a>",
"    ]. The best studied of these pharmacogenetic factors are inherited polymorphisms in uridine diphospho glucuronosyltransferase 1A1 (UGT1A1). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link\">",
"     \"Overview of pharmacogenomics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     UGT1A1 polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The active form of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (SN-38) is metabolized by the polymorphic enzyme UGT1A1. Intratumoral enzymatic activity is reduced in individuals who inherit genetic polymorphisms such as the UGT1A1*28 allele (also known as TA indel or UGT1A1",
"    <span class=\"nowrap\">",
"     7/7).",
"    </span>",
"    Approximately 10 percent of the North American population is homozygous for the UGT1A1*28 allele (which is responsible for Gilbert's syndrome); an additional 40 percent are heterozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link&amp;anchor=H4#H4\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial reports suggested that UGT1A1*28 homozygotes (and heterozygotes to a lesser degree) were at high risk for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -related gastrointestinal (GI) toxicity and neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/66,68-72\">",
"     66,68-72",
"    </a>",
"    ]. However, more recent data indicate that the magnitude of the problem (particularly the association with worse diarrhea) was not as great as initially suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/67,69,73-75\">",
"     67,69,73-75",
"    </a>",
"    ]. Nevertheless, these results led some to recommend that all patients initiating irinotecan therapy undergo genetic testing for relevant alleles.",
"   </p>",
"   <p>",
"    Early studies and a meta-analysis suggested that the effect was dose dependent and not seen in patients receiving low doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (100 to 125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/74\">",
"     74",
"    </a>",
"    ]); however a later meta-analysis concluded that inheritance of UGT1A1*28 was associated with an increased risk of neutropenia at all doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/76\">",
"     76",
"    </a>",
"    ]. However, the relative risk (RR) for neutropenia at doses &ge;250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    was significantly higher (RR 7.0, 95% CI 3.10-16.78) than that for",
"    <sup>",
"    </sup>",
"    lower doses (80 to 145",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly, RR 2.43, 95% CI 1.34 to 4.39).",
"   </p>",
"   <p>",
"    In 2005, the FDA recommended modification of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    drug labeling to specify that individuals who are homozygous for the UGT1A1 *28 allele are at increased risk for neutropenia following treatment with irinotecan. Genetic testing for the presence of the UGT1A1*28 allele is available, and the FDA-approved label recommends testing. The manufacturer also recommends reducing the initial irinotecan dose in those who are homozygous for UGT 1A1*28 to reduce the likelihood of dose-limiting neutropenia.",
"   </p>",
"   <p>",
"    However, routine use of this assay in all patients who are to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for treatment of metastatic disease has not been widely accepted for several reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, the clinical relevance of identifying homozygotes is unclear. Only about 1 in 10 patients will be identified as being homozygous, and the excess risk of severe neutropenia that is attributable to the inheritance of this polymorphism seems to be small, particularly at doses &lt;150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/74\">",
"       74",
"      </a>",
"      ]. As an example, the risk of severe neutropenia with the first course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      in one study was 14 versus 2 percent in those with the UGT1A1*28 and wild-type allele, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/69\">",
"       69",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, others report a much higher rate of grade 3 or 4 hematologic toxicity over an entire course of treatment in patients receiving irinotecan doses &lt;150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly who inherit the",
"      <span class=\"nowrap\">",
"       7/7",
"      </span>",
"      variant as compared to carriers of the",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       6/6",
"      </span>",
"      allele (48 versus 10 and 8 percent, respectively), a higher rate of hospitalization during therapy, and greater short-term death rate as well [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/78\">",
"       78",
"      </a>",
"      ]. Whether outcomes would have been altered by upfront identification of",
"      <span class=\"nowrap\">",
"       7/7",
"      </span>",
"      carriers and initial dose modification is unclear.",
"     </li>",
"     <li>",
"      Whether initial dose reduction is needed for UGT1A1*28 homozygotes, and how much to reduce the dose remain unresolved issues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/72,79\">",
"       72,79",
"      </a>",
"      ]. Some have recommended an initial 20 percent dose reduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/80\">",
"       80",
"      </a>",
"      ], but there is no consensus on this point. Others have suggested that patients without the",
"      <span class=\"nowrap\">",
"       *28/*28",
"      </span>",
"      genotype can tolerate much higher doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      than are contained in standard regimens such as FOLFIRI (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/81\">",
"       81",
"      </a>",
"      ]. However, whether the risk to benefit ratio can be improved by selecting the irinotecan dose based on genotype will require prospective genotype-driven trials.",
"     </li>",
"     <li>",
"      Inheritance of UGT1A1*28 polymorphisms seems to account for only a fraction of the observed variability in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/64,82\">",
"       64,82",
"      </a>",
"      ]. It is likely that both inherited (eg, alternative UGT1A haplotypes or polymorphisms in other genes involved in irinotecan disposition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/64,82-84\">",
"       64,82-84",
"      </a>",
"      ]) and nongenetic factors (eg, pretreatment bilirubin levels, gender, smoking, co-medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/61,64,85-87\">",
"       61,64,85-87",
"      </a>",
"      ]) contribute to a patient's risk of irinotecan-related toxicity. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Pharmacokinetic variability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cost-effectiveness of pharmacogenetic testing for UGT1A1 before",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      administration remains uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all of these reasons, the clinical utility of pretreatment testing for the UGT1A1 *28 allele remains uncertain.",
"   </p>",
"   <p>",
"    Emerging work suggests that hepatic functional imaging (HFI) might represent a promising approach for assessing hepatic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    handling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/63\">",
"     63",
"    </a>",
"    ]. However, whether those patients at risk for irinotecan-related toxicity are best identified by HFI or a combined approach of HFI plus drug response gene polymorphisms remains to be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Irinotecan plus capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (XELIRI, CAPIRI) has been extensively explored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. Reports of excessive toxicity (principally GI) have prompted alteration in dose and administration schedule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/51,93\">",
"     51,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efficacy has been addressed in the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II study, in which 52 patients with previously untreated mCRC received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 day cycle) (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ), the response rate was 50 percent, TTP 7.8 months, and median survival 16.8 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/91\">",
"       91",
"      </a>",
"      ]. With the exception of GI toxicity, the regimen was more toxic in patients over the age of 65.",
"     </li>",
"     <li>",
"      On the other hand, inferior outcomes with this regimen as compared to FOLFIRI were noted in the randomized BICC-C trial, in which 430 patients were enrolled to FOLFIRI, modified IFL, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 28 days plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1, all arms with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , with a later amendment that added",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to the chemotherapy arms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/51\">",
"       51",
"      </a>",
"      ]. Compared to FOLFIRI alone,",
"      <span class=\"nowrap\">",
"       capecitabine/irinotecan",
"      </span>",
"      was associated with significantly higher rates of nausea, vomiting, diarrhea, febrile neutropenia, and dehydration as well as significantly worse PFS (5.8 versus 7.6 months), and a trend towards inferior median survival (18.9 versus 23.1 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This regimen should probably not be used as first-line therapy until its comparability to FOLFIRI is better defined. In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus the oral agent S-1 may be a reasonable alternative to FOLFIRI after failure of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen. (See",
"    <a class=\"local\" href=\"#H5025419\">",
"     'S-1 plus oxaliplatin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Irinotecan after oxaliplatin failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;As",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimens are increasingly used as first-line therapy of mCRC, the efficacy of salvage",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    is emerging as an important issue. Although limited, the most mature data from three series suggest response rates between 4 and 20 percent, and PFS of 2.5 to 7.1 months, respectively for patients receiving a FOLFIRI-like regimen after progression on FOLFOX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal sequence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing chemotherapy remains unresolved, and may differ between patients based on tumor-related heterogeneity and pharmacogenetic issues. Exposure to all active agents is probably more important than the specific sequence of administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Nevertheless, most American oncologists initiate chemotherapy for mCRC with FOLFOX, using irinotecan alone or irinotecan-based regimens such as FOLFIRI as second-line therapy after the failure of FOLFOX.",
"   </p>",
"   <p>",
"    S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur, chlorohydroxy dihydropyridine (a potent DPD inhibitor) and oxonic acid (which inhibits phosphorylation of intestinal 5-FU, which is thought to be responsible for treatment-related diarrhea). It is available in some countries outside of the US. Where S-1 is available,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus S-1 may be a reasonable alternative to FOLFIRI after failure of an initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    with",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    is more effective than",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    alone, and the triplet combination represents a standard option for first-line therapy of mCRC. At present, most American oncologists use irinotecan-based regimens in the second-line setting, after failure of initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based therapy. However, an irinotecan-based regimen could be considered initially in a patient with a relative contraindication to oxaliplatin (eg, preexisting neuropathy or prior exposure to oxaliplatin in the adjuvant setting).",
"   </p>",
"   <p>",
"    For patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus 5-FU",
"    <span class=\"nowrap\">",
"     /LV,",
"    </span>",
"    the weekly bolus regimen (the IFL or \"Saltz\" regimen) should no longer be considered an appropriate administration schedule for triplet therapy. Regimens that contain short-term infusional 5-FU (FOLFIRI (",
"    <a class=\"graphic graphic_table graphicRef76300 \" href=\"mobipreview.htm?19/2/19502\">",
"     table 3",
"    </a>",
"    ) or the Douillard regimen) (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) are preferred because of their more favorable toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Irinotecan plus 5-FU'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns have been raised about potentially inferior efficacy and greater toxicity using the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for patients who wish to avoid short-term infusional 5-FU (which requires a central venous catheter and an ambulatory infusion pump). This approach has not been widely adopted. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Irinotecan plus capecitabine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Individuals who inherit a genetic polymorphism in the drug-metabolizing enzyme UGT1A1 (the UGT1A1*28 allele) may have more severe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -related neutropenia and diarrhea; the available data are conflicting. While testing for the presence of this allele is available (the Invader UGT1A1 Molecular Assay), whether its use is warranted for all patients who are to receive irinotecan is unclear. Whether initial dose reduction is needed for UGT1A1*28 homozygotes, and the precise dose reduction that is warranted in this patient population remain controversial areas. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Pharmacokinetic variability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The contribution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based chemotherapy is discussed below. (See",
"    <a class=\"local\" href=\"#H51\">",
"     'Agents targeting the EGFR'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OXALIPLATIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    is the only platinum derivative approved to date with significant activity in mCRC in combination with 5-FU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Oxaliplatin alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early phase II data suggested activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    alone for first-line therapy (20 to 25 percent response rate in two separate studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]). However, subsequent randomized data (albeit for second-line therapy) have shown a fairly low level of activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/103\">",
"     103",
"    </a>",
"    ]. As a result, most clinicians consider single agent oxaliplatin to be an inappropriate choice for first-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     First-line oxaliplatin plus 5-FU/LV",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    synergizes with 5-FU. At least three trials show significantly greater response rates and progression-free survival (PFS) but similar overall survival with oxaliplatin plus short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (FOLFOX) compared to 5-FU plus leucovorin (LV) alone in the first-line setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. FOLFOX has comparable activity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    given as a short-term infusion (FOLFIRI) for patients with mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/94,107\">",
"     94,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Oxaliplatin/FU/LV versus FU/LV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    was initially shown in a trial in which 420 patients with previously untreated mCRC were randomly assigned to LV (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily over two hours) followed by a 5-FU bolus (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily) and a 22-hour infusion of 5-FU (600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily) for two consecutive days every two weeks (the de Gramont regimen), either alone or with oxaliplatin (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 over two hours), a regimen termed FOLFOX4 (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/104\">",
"     104",
"    </a>",
"    ]. Patients treated with FOLFOX4 had a significantly higher objective response rate (51 versus 22 percent) and longer PFS (9 versus 6.2 months) but similar median overall survival (16.2 versus 14.7 months). Grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    neutropenia (42 versus 5 percent) and diarrhea (12 versus 5 percent) were more common with oxaliplatin.",
"   </p>",
"   <p>",
"    Results were similar in a second multicenter study, in which 410 patients were randomly assigned to short-term infusional LV-modulated 5-FU or FOLFOX6 (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/108\">",
"     108",
"    </a>",
"    ]. Initial combination treatment was associated with a significantly better objective response rate (58 versus 24 percent) and PFS (7.6 versus 5.3 months), but median overall survival (16.2 versus 16.4 months) was similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Oxaliplatin/FU/LV versus irinotecan/FU/LV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data from head to head comparisons suggest that outcomes with first-line",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"      oxaliplatin",
"     </a>",
"     /5-FU/LV",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"      irinotecan",
"     </a>",
"     /5-FU/LV",
"    </span>",
"    are similar. While a survival benefit for the oxaliplatin-containing regimen compared to bolus",
"    <span class=\"nowrap\">",
"     irinotecan/5-FU/LV",
"    </span>",
"    (IFL) was suggested in a United States Cooperative Group trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/55\">",
"     55",
"    </a>",
"    ], two smaller (ie, not statistically powered for a noninferiority comparison) European trials that used short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (ie, FOLFIRI) as the comparator did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/94,107\">",
"     94,107",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Irinotecan plus 5-FU'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      INT 9741 &mdash; Intergroup (INT) 9741 randomly assigned patients to IFL,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"        oxaliplatin",
"       </a>",
"       /5-FU/LV",
"      </span>",
"      using the FOLFOX4 regimen (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ), or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      plus oxaliplatin (IROX, oxaliplatin 85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      plus irinotecan 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      both administered on day 1 every three weeks). The trial was unblinded early by the Data Safety Monitoring Committee because FOLFOX proved more effective and less toxic than IFL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/52\">",
"       52",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The initial analysis included 795 patients who were assigned to IFL, FOLFOX4, or IROX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/55\">",
"       55",
"      </a>",
"      ]. FOLFOX4 was significantly superior to IFL in terms of objective response rate (45 versus 31 percent), time to tumor progression (TTP, 8.7 versus 6.9 months), and median overall survival (20 versus 15 months). Patients receiving IFL had significantly higher rates of alopecia, diarrhea, nausea, vomiting, and febrile neutropenia, but significantly fewer paresthesias than those receiving FOLFOX4. More patients discontinued FOLFOX for reasons other than disease progression (60 versus 25 percent of the IFL group), presumably reflecting cumulative neuropathy.",
"      <br/>",
"      <br/>",
"      In a later update, FOLFOX was also superior to IROX in terms of response rate (43 versus 36 percent), TTP (9.2 versus 6.7 months), and overall survival (19.5 versus 17.3 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/109\">",
"       109",
"      </a>",
"      ]. Patients over the age of 70 receiving IROX had significantly higher rates of grade 3 or worse hematologic toxicity.",
"     </li>",
"     <li>",
"      European trials &mdash; In contrast to the results from INT trial 9741, in which",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      was given in combination with bolus",
"      <span class=\"nowrap\">",
"       5-FU/LV,",
"      </span>",
"      two European trials suggest similar efficacy for combinations of irinotecan or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      with short-term infusional LV-modulated 5-FU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/94,107\">",
"       94,107",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      One trial compared a different schedule of FOLFOX (every two weeks oxaliplatin 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      plus LV 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and 5-FU bolus 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      followed by 5-FU 2.4 to 3.0",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 46 hours by continuous infusion, termed FOLFOX6 [(",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      )]) versus FOLFIRI, the same de Gramont",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      regimen plus irinotecan (180",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 every two weeks) in 226 previously untreated patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/94\">",
"       94",
"      </a>",
"      ]. Patients were allowed to crossover to the alternative regimen at progression. Response rates were similar (54 and 56 percent for FOLFOX6 and FOLFIRI, respectively), and the PFS (8 versus 8.5 months) and median survival (20.6 and 21.5 months, respectively) rates were similar.",
"      <br/>",
"      <br/>",
"      A lack of superiority for FOLFOX was also noted in an Italian trial, which randomly assigned 360 patients with previously untreated mCRC to one of the following groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/107\">",
"       107",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Every other week",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (180",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1), LV (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over two hours in days 1 and 2) with each dose of LV followed by 5-FU (400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      bolus and 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 22 hours), a regimen termed the Douillard regimen (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       Oxaliplatin",
"      </a>",
"      plus the de Gramont regimen of",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      (FOLFOX4, (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ))",
"      <br/>",
"      <br/>",
"      Overall response rates were similar (31 and 34 percent, respectively), as were PFS, median survival (14 versus 15 months), and toxicity profiles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Differences in trial design may provide at least part of the explanation for these disparate results. In INT 9741, 5-FU was delivered differently (bolus or infusion) in the two arms containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , whereas it was given by bolus alone with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ; delivery of 5-FU and LV was the same on both arms of the two European studies.",
"   </p>",
"   <p>",
"    The need for infusional 5-FU in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    combination regimens is unclear. At least one phase II study reports comparable results with a less complex bolus regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/110\">",
"     110",
"    </a>",
"    ]. However, at present, administration with short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    is considered a standard approach.",
"   </p>",
"   <p>",
"    The contribution of the anti-VEGF monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to the efficacy of the FOLFOX regimen is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , short-term infusional 5-FU and LV is a standard treatment option for first-line treatment of mCRC. Most American oncologists use a modification of the FOLFOX6 regimen in which the oxaliplatin dose is the same as in FOLFOX4 (modified FOLFOX6) (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 4",
"    </a>",
"    ). The available data support the view that efficacy of first-line FOLFOX is similar to that of FOLFIRI. The choice of which regimen to use should be based upon expected toxicities of each regimen in the context of coexisting conditions for any given patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Capecitabine plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and tolerability of the XELOX (also called CAPOX) combination has been explored extensively for both first-line and second-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/111-119\">",
"     111-119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best regimen is uncertain. In three separate phase II studies in previously untreated patients, objective response rates using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days) were 36, 42 and 55 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/111-113\">",
"     111-113",
"    </a>",
"    ], and the median survival in one of these trials was 19.5 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/112\">",
"     112",
"    </a>",
"    ]. Tolerability was better in two studies (one of which focused on patient over the age of 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]) than in the third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, lower initial doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) were combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000 mg orally twice daily for 14 of every 21 days) in a trial that focused on first-line treatment of patients 70 years of age or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/117\">",
"     117",
"    </a>",
"    ]. If tolerated, the oxaliplatin dose could be increased to 110",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and then to 130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for the second and third cycles. The objective response rate was 41 percent and the median overall survival 14.4 months (nearly identical to results with higher dose oxaliplatin in a separate phase II trial conducted in an elderly population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/111\">",
"     111",
"    </a>",
"    ]). Treatment was well tolerated with only 5 percent of patients developing grade 3 or 4 hematologic toxicity, 8 percent peripheral neuropathy, and 13 percent severe hand-foot syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     First-line XELOX versus FOLFOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials have explored whether XELOX provides similar efficacy and tolerability as other",
"    <span class=\"nowrap\">",
"     fluoropyrimidine/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"      oxaliplatin",
"     </a>",
"    </span>",
"    combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/116,118-121\">",
"     116,118-121",
"    </a>",
"    ]; all suggest comparable efficacy, but a different toxicity profile. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The phase II TREE-1 trial randomly assigned 150 patients to modified FOLFOX6 (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 4",
"      </a>",
"      ), CAPOX (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      1000 mg twice daily for 14 of every 21 days plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1), or bFOL (bolus 5-FU 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      and LV 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for three of every four weeks plus oxaliplatin 85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 15) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/116\">",
"       116",
"      </a>",
"      ]. The differences between FOLFOX and CAPOX in response rates, TTP and median survival were not significant (",
"      <a class=\"graphic graphic_table graphicRef66587 \" href=\"mobipreview.htm?8/53/9053\">",
"       table 5",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Patients in the CAPOX group had the highest rates of hand-foot syndrome, grade 3 or 4",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      and neuropathy (38 and 21 percent), and more often discontinued therapy because of toxicity. The FOLFOX6 group had the highest rate of grade 3 or 4 neutropenia (53 versus 15 percent with CAPOX). Rates of grade 3 or 4 diarrhea were the same (31 percent) in both groups.",
"     </li>",
"     <li>",
"      In the 474-patient AIO trial comparing XELOX using a unique",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      schedule (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 14 of every 21 days plus oxaliplatin 70",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 and day 8) versus FUFOX (5-FU 2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours, LV 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      and oxaliplatin 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, 15, and 22 of every 5 week cycle) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/118\">",
"       118",
"      </a>",
"      ]. As with TREE 1, the differences between FUFOX and CAPOX in response rates (54 versus 48 percent), PFS (8 versus 7.1 months) and median survival (18.8 versus 16.8 months) were not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review of trials comparing first-line CAPOX versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus infusional",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    concluded that CAPOX was associated with a significantly lower response rate, but this did not translate into lower PFS or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/122\">",
"     122",
"    </a>",
"    ]. Thrombocytopenia and hand foot syndrome were consistently more prominent with CAPOX, but heterogeneity in the trials precluded a valid comparison of rates of severe diarrhea or neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;XELOX (also called CAPOX,) could be considered for first-line therapy of mCRC in patients for whom ambulatory infusional therapy using a pump is not feasible or desired. The available data suggest that XELOX has approximately similar antitumor efficacy, but there is a possibility of more toxicity (especially thrombocytopenia and hand-foot syndrome, possibly diarrhea) as compared to infusional",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"      oxaliplatin",
"     </a>",
"    </span>",
"    combinations.",
"   </p>",
"   <p>",
"    For American patients, we consider the standard regimen to be",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    850",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days (as was used in the TREE-2 trial) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 over two hours (",
"    <a class=\"graphic graphic_table graphicRef61781 \" href=\"mobipreview.htm?13/60/14286\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/116,119\">",
"     116,119",
"    </a>",
"    ]. Oncologists in Europe and Asia more commonly start with capecitabine 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily, as was used in TREE-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lower",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    dose (eg, 85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours on day 1) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (850 or 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily on days 2 to 15) could be considered for elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/117\">",
"     117",
"    </a>",
"    ]. More intensive regimens (eg, week on, week off therapy with both capecitabine and oxaliplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/113\">",
"     113",
"    </a>",
"    ]) may be more active, but direct comparisons with standard doses are not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5025419\">",
"    <span class=\"h2\">",
"     S-1 plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur, chlorohydroxy dihydropyridine (a potent DPD inhibitor), and oxonic acid (which inhibits phosphorylation of intestinal 5-FU, which is thought to be responsible for treatment-related diarrhea). It is available in some countries outside of the US. The combination of S-1 plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (SOX) was directly compared to XELOX in a multicenter randomized Korean phase III trial of 340 patients with previously untreated mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/123\">",
"     123",
"    </a>",
"    ]. The design was characterized as a non-inferiority trial with an upper boundary of the progression-free survival (PFS) hazard ratio of 1.43 (meaning that a 43 percent detriment in PFS would have been considered acceptable to define noninferiority). SOX was statistically noninferior to standard CAPOX in terms of PFS (HR 0.79, 95% CI 0.6- 1.04), and demonstrated a significantly higher response rate (48 versus 36 percent), but more grade 3 or 4 neutropenia, thrombocytopenia, and diarrhea. Given the global differences in tolerability of fluoropyrimidines, and the lack of biologic agents in either arm of this trial, it is difficult to conclude that S-1 plus oxaliplatin represents an acceptable first-line chemotherapy regimen for mCRC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Oxaliplatin after irinotecan failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based therapy in patients failing an initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimen was addressed in four multicenter trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early crossover trial, the response rate with FOLFOX6 in patients failing initial FOLFIRI was 15 percent, and the PFS was 4.2 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest trial, conducted in the United States and Canada, randomly allocated 812",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -refractory patients to one of three different treatment groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/103,124\">",
"       103,124",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       Oxaliplatin",
"      </a>",
"      alone (85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every two weeks)",
"     </li>",
"     <li>",
"      The de Gramont",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over two hours, followed by 5-FU [bolus 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and a 22-hour infusion of 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day], days 1 and 2 every two weeks, FOLFOX4) (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the latest report, the objective response rate with FOLFOX4 was significantly higher than with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    alone or",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (9.6 versus 1.1 and 0.7 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/124\">",
"     124",
"    </a>",
"    ]. Median TTP was also significantly longer with FOLFOX4 as compared to",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (4.2 versus 2.1 months), and more patients had symptomatic benefit (28 versus 15 percent). Median overall survival was similar (9.8 versus 8.7 months). The higher frequency of grade 3 or 4 toxicity with FOLFOX4 (ie, diarrhea, nausea, vomiting, neutropenia) did not translate into a higher rate of treatment discontinuation or mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/103,124\">",
"     103,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar results were noted in a US trial, in which 214 patients failing sequential 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      monotherapy were randomized to the de Gramont regimen of",
"      <span class=\"nowrap\">",
"       5-FU/LV",
"      </span>",
"      or FOLFOX4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/125\">",
"       125",
"      </a>",
"      ]. Patients treated with FOLFOX4 had a higher response rate (13 versus 2 percent) and TTP (4.8 versus 2.4 months), but similar survival.",
"     </li>",
"     <li>",
"      Second-line FOLFOX4 was directly compared to XELOX (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 30 minutes on day 1 every three weeks plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      orally twice daily on days 1 to 14) in a phase III trial of 627 patients failing initial",
"      <span class=\"nowrap\">",
"       5-FU/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"        irinotecan",
"       </a>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/126\">",
"       126",
"      </a>",
"      ]. Results with XELOX were not inferior to FOLFOX4 in terms of response rates, TTP, or median overall survival (12.5 and 11.9 months for FOLFOX and XELOX). Toxicity profiles were also comparable, with the exception of fewer grade 3 or 4 neutropenia (5 versus 35 percent), and more grade 3 or 4 diarrhea (19 versus 5 percent) and hand-foot syndrome (4 versus &lt;1 percent) with XELOX. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Capecitabine plus oxaliplatin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the US,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is approved in combination with infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (FOLFOX4) for patients who recur or progress during or within six months of completion of first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based therapy.",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"      Capecitabine",
"     </a>",
"     /oxaliplatin",
"    </span>",
"    could be considered in patients who desire to avoid a central venous line ambulatory infusion pump, although increasingly, oxaliplatin is being administered through a central line because of pain with peripheral vein administration. The contribution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to the efficacy of",
"    <span class=\"nowrap\">",
"     oxaliplatin/fluoropyrimidine",
"    </span>",
"    regimens is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and 5-FU-based combination regimens is dependent both on the oxaliplatin dose and the schedule of",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"    As previously noted, in the INT 9741 trial, treatment-related toxicity rates were acceptable in the group treated with FOLFOX4 (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    oxaliplatin), while they were unacceptable with oxaliplatin 130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H29\">",
"     'First-line oxaliplatin plus 5-FU/LV'",
"    </a>",
"    above.) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others report less toxicity when smaller doses of biweekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    are combined with weekly bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/127\">",
"     127",
"    </a>",
"    ]. However, a randomized trial comparing this regimen to FOLFOX4 has not been performed.",
"   </p>",
"   <p>",
"    The relationship between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    dose, efficacy, and toxicity was evaluated in a pooled summary of phase II studies in which different oxaliplatin doses (80 to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    were added to every two week 5-FU plus LV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/128\">",
"     128",
"    </a>",
"    ]. A total of 47 patients received low dose intensity oxaliplatin (&le;85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per two weeks) while 79 received high dose intensity (&gt;85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks) therapy. Higher doses were associated with a higher objective response rate (39 versus 19 percent), and a greater chance of six month PFS (52 versus 36 percent). The higher dose intensity was not associated with an increase in severe neurotoxicity or GI toxicity.",
"   </p>",
"   <p>",
"    However, these were retrospective comparisons that did not take into account the heterogeneity of patients treated with the different regimens, leaving open the question of whether dose intensity does make a difference in efficacy when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is combined with 5-FU and LV. A role for intensifying the oxaliplatin dose above 85",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks has not been established in prospective studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Neurotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major dose-limiting toxicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is neurotoxicity. There are two distinct syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reversible cumulative sensory neuropathy, with distal sensory loss and dysesthesias. The incidence of grade 3 neuropathy with cumulative doses of 850",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      is 10 to 15 percent, and rises thereafter.",
"     </li>",
"     <li>",
"      An acute neurosensory complex, which consists of striking paresthesias and dysesthesias of the hands, feet, and perioral region, jaw tightness, and unusual pharyngo-laryngo-dysesthesias. Patients need to be warned not to drink cold fluids in the days around their",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      infusions. Lengthening the infusion duration from two to six hours can prevent recurrence of the pseudolaryngospasm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early data suggests that inheritance of certain polymorphisms in the drug metabolizing enzyme glutathione-S transferase gene (GSTP1-105) influences the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -induced neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/129\">",
"     129",
"    </a>",
"    ]. However, further study is needed before routine genetic testing for GSTP1-105 genotype can be recommended as a means of selecting patients for oxaliplatin-based chemotherapy.",
"   </p>",
"   <p>",
"    Preliminary data from randomized, placebo-controlled trials in the adjuvant and metastatic disease settings suggest potential benefit for IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    (1 gram) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (1 gram) pre- and post-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in reducing rates of chronic cumulative neurosensory toxicity. Approaches to diminishing oxaliplatin neurotoxicity are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=see_link&amp;anchor=H15#H15\">",
"     \"Neurologic complications of platinum-based chemotherapy\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infusion reactions, characterized by rash, fever, ocular and respiratory symptoms of varying severity, have been reported in up to 25 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . Patients with mild reactions can continue to be treated with oxaliplatin by premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and steroids, and by lengthening the infusion duration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreasing the dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H25#H25\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Oxaliplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Chronomodulated schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether circadian-modulated administration schedules of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    with fluoropyrimidines are less toxic than conventional scheduling is unclear; the data are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/17,106,130-132\">",
"     17,106,130-132",
"    </a>",
"    ]. The data are insufficient to conclude that chronomodulated administration of 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and oxaliplatin is a valuable strategy. In the absence of a clear survival advantage for chronomodulated therapy, most ongoing studies in the United States are not utilizing this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     OXALIPLATIN PLUS IRINOTECAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to improve on current therapy, combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    with and without",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    have been studied, both as first-line and second-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Second-line IROX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of second-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (IROX) was studied in a randomized phase II trial that assigned 62 patients with 5-FU-refractory disease to IROX or a triple regimen of",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    plus alternating irinotecan and oxaliplatin",
"    <span class=\"nowrap\">",
"     (FC/FO)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/133\">",
"     133",
"    </a>",
"    ]. The IROX regimen was associated with a higher response rate (23 versus 6 percent), slightly longer median survival (12.3 versus 9.8 months), and a more favorable toxicity profile.",
"   </p>",
"   <p>",
"    The clinical significance of these findings is limited in that most patients receive an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing regimen as first-line therapy. Others report a 39 percent response rate with oxaliplatin plus IFL in patients failing first-line IFL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/134\">",
"     134",
"    </a>",
"    ]. Whether these results are better than can be achieved by FOLFOX alone in this setting is unclear, since randomized trials are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     First-line IROX or FOLFOXIRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials are evaluating the best method of combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , with or without",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    for first-line therapy. Preliminary reports suggest manageable toxicity and a high degree of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/55,135-141\">",
"     55,135-141",
"    </a>",
"    ], but whether this approach is superior to other irinotecan or oxaliplatin-based regimens is unclear.",
"   </p>",
"   <p>",
"    The IROX regimen was inferior to first-line FOLFOX4 in United States Intergroup (INT) trial 9741, and it was more toxic in elderly individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/140\">",
"     140",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Oxaliplatin/FU/LV versus irinotecan/FU/LV'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Similarly, a report of the FIRE trial (IROX versus FOLFIRI as first-line treatment of CRC) suggested that the regimens had similar efficacy (objective response rate 41 percent with both regimens, median survival 22 and 19 months for FOLFIRI and IROX, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High rates of successful resection for initially unresectable liver metastases have been reported for the FOLFOXIRI (folinic acid, 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , (",
"    <a class=\"graphic graphic_table graphicRef70559 \" href=\"mobipreview.htm?3/32/3599\">",
"     table 7",
"    </a>",
"    )) regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/143\">",
"     143",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Conversion therapy for initially unresectable metastases'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=see_link\">",
"     \"Treatment protocols for colorectal cancer\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    However, two phase III trials comparing FOLFOXIRI with the Douillard",
"    <span class=\"nowrap\">",
"     irinotecan/5-FU/LV",
"    </span>",
"    regimen (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ) have come to opposite conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An Italian trial comparing a six-month course of FOLFOXIRI versus FOLFIRI suggests significantly better outcomes with FOLFOXIRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/138,141\">",
"       138,141",
"      </a>",
"      ]. Benefits of a six month course of FOLFOXIRI included a significantly higher response rate (the primary endpoint, 66 versus 41 percent), and a greater number of patients able to undergo complete secondary surgical resection of liver metastases (36 versus 12 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/138\">",
"       138",
"      </a>",
"      ]. In the latest report, at a median follow-up of over 60 months, FOLFIRINOX was associated with significantly longer median progression-free survival (PFS, 9.8 versus 6.8 months), and overall survival (23.4 versus 16.7 months), with a five year survival rate of 15 versus 8 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/141\">",
"       141",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Compared with FOLFIRI, FOLFOXIRI was associated with significantly higher rates of grade 2 or 3 peripheral neuropathy (19 versus 0 percent) and of grade 3 or 4 neutropenia (50 versus 28 percent), but the incidence of febrile neutropenia (5 versus 3 percent) and of grade 3 or 4 diarrhea (20 versus 12 percent) were not significantly different [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/138\">",
"       138",
"      </a>",
"      ]. The initial administration of FOLFIRINOX did not have a negative impact on outcomes of treatment after disease progression (a second objective response to FOLFIRINOX was seen in 22 percent of patients initially treated with FOLFIRINOX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/141\">",
"       141",
"      </a>",
"      ]), underscoring the importance of rechallenging patients who responded to first-line treatment with the same agents used first-line. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H4881383#H4881383\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Continuum of care model'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Based upon these data, and a preliminary report suggesting that the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to FOLFOXIRI is highly active and well tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/144\">",
"       144",
"      </a>",
"      ], a phase III trial comparing bevacizumab plus either FOLFOXIRI or FOLFIRI was undertaken (the TRIBE trial). In a preliminary report presented at the 2013 ASCO Gastrointestinal Cancers symposium, FOLFOXIRI-bevacizumab was associated with a significantly better overall response rate (65 versus 53 percent) and progression-free survival rate (median 12.2 versus 9.7 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/145\">",
"       145",
"      </a>",
"      ]. Grade 3 to 4 toxic effects that were more common with FOLFOXIRI included diarrhea (18 versus 10 percent), stomatitis (8 versus 4 percent), neutropenia (49 versus 20 percent), and peripheral neurotoxicity (5 versus 0 percent).",
"     </li>",
"     <li>",
"      In contrast, an Hellenic Oncology group trial of 283 patients with previously untreated mCRC noted no significant benefit for FOLFOXIRI versus the Douillard regimen of",
"      <span class=\"nowrap\">",
"       5-FU/LV/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"        irinotecan",
"       </a>",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ) in terms of median overall survival (21.5 versus 19.5 months), time to tumor progression (TTP, 8.4 versus 6.9 months), or objective response rate (43 versus 34 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/135\">",
"       135",
"      </a>",
"      ]. However, the FOLFOXIRI regimen used in this trial contained smaller doses of irinotecan,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , and FU.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results are promising, regimens that contain both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    are not yet a standard approach for first-line or salvage treatment after failure of an irinotecan or oxaliplatin-based regimen, for several reasons, and we do not suggest their use outside of a clinical trial, with few exceptions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H10#H10\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Initial three-drug combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible exceptions include FOLFOXIRI for conversion therapy in patients with initially unresectable liver metastases who might become candidates for surgical resection if the response to chemotherapy is sufficient, and perhaps IROX in the unusual case of a patient with severe DPD deficiency. This approach should be used cautiously in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/140\">",
"     140",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Choice of regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     AGENTS TARGETING VEGF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of a blood supply is a necessary prerequisite for tumor growth. The dominant factor controlling angiogenesis is vascular endothelial growth factor (VEGF). Inhibition of VEGF by a variety of methods produces a marked antitumor response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23212813\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516273937\">",
"    <span class=\"h3\">",
"     First-line use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    (Avastin&reg;) is a humanized monoclonal antibody (MoAb) targeting VEGF. Adding bevacizumab to a variety of first-line regimens used for mCRC improves outcomes modestly. However, these advances come at a cost of treatment-related side effects, including bleeding, hypertension, bowel perforation, and thromboembolic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h4\">",
"     Irinotecan regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    was initially shown in a trial of 813 patients who were randomly assigned to IFL with or without bevacizumab (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/146\">",
"     146",
"    </a>",
"    ]. Bevacizumab improved the objective response rate (45 versus 35 percent), and significantly improved time to tumor progression (TTP, 11 versus 6 months) and median survival (20 versus 16 months). Following publication of these data, bevacizumab received broad approval in the US in combination with 5-FU for first-line treatment of mCRC.",
"   </p>",
"   <p>",
"    The above trials combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    with bolus IFL, a regimen that has fallen out of favor due to the more favorable GI toxicity profile of regimens that contain short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    (eg, FOLFIRI) (",
"    <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"     table 1",
"    </a>",
"    ). The available data on bevacizumab plus FOLFIRI are limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the complex BICC-C trial, patients with previously untreated mCRC were assigned to FOLFIRI, modified IFL, or",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"        capecitabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"        irinotecan",
"       </a>",
"       ,",
"      </span>",
"      all arms with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      ; a later amendment added",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to patients on the FOLFIRI and IFL arms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/51\">",
"       51",
"      </a>",
"      ]. The median PFS was 11.2 months in the small group of 61 patients receiving",
"      <span class=\"nowrap\">",
"       bevacizumab/FOLFIRI",
"      </span>",
"      (8.3 months for",
"      <span class=\"nowrap\">",
"       bevacizumab/IFL),",
"      </span>",
"      and the objective response rate was 58 percent (53 percent with",
"      <span class=\"nowrap\">",
"       bevacizumab/IFL).",
"      </span>",
"      In a later report, at a median follow-up of 34 months, median survival in the group receiving",
"      <span class=\"nowrap\">",
"       FOLFIRI/bevacizumab",
"      </span>",
"      was 28 months while it was 19.2 months with",
"      <span class=\"nowrap\">",
"       bevacizumab/IFL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/147\">",
"       147",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparable median overall survival results were noted in the BEAT study, in which 1927 previously untreated patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      plus a chemotherapy regimen chosen by the individual clinician [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/148\">",
"       148",
"      </a>",
"      ]. Median PFS and overall survival for the 503 patients treated with",
"      <span class=\"nowrap\">",
"       FOLFIRI/bevacizumab",
"      </span>",
"      was 11.6 and 23.7 months, respectively.",
"     </li>",
"     <li>",
"      On the other hand, a lack of survival benefit for the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to FOLFIRI was shown in a European trial of 222 treatment-na&iuml;ve patients with mCRC (median survival 25 versus 22 months, p = 0.14) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h4\">",
"     Oxaliplatin regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen has been addressed in several trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the phase II randomized TREE-2 trial, 223 previously untreated patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two weeks) and one of the three different",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      and 5-FU-containing regimens used in the TREE 1 trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/116\">",
"       116",
"      </a>",
"      ]. Bevacizumab substantially improved the response rates of all of the regimens (",
"      <a class=\"graphic graphic_table graphicRef66587 \" href=\"mobipreview.htm?8/53/9053\">",
"       table 5",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Median overall survival was 23.7 months for the combined groups receiving bevacizumab (versus 18.2 months for the combined non-bevacizumab-treated groups). This is one of the highest median survival values ever reported. However, bevacizumab also increased rates of grade 3 or 4 hypertension (",
"      <a class=\"graphic graphic_table graphicRef66587 \" href=\"mobipreview.htm?8/53/9053\">",
"       table 5",
"      </a>",
"      ), bowel perforation (2 percent overall), impaired wound healing (n = 3) and bleeding events (45 versus 22 percent in the groups treated with FOLFOX with and without bevacizumab).",
"     </li>",
"     <li>",
"      Comparable PFS and overall survival results were noted in the BEAT study in which previously untreated patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      with a specific regimen chosen by the clinician [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/148\">",
"       148",
"      </a>",
"      ]. Median PFS and overall survival for the 552 patients who received",
"      <span class=\"nowrap\">",
"       FOLFOX/bevacizumab",
"      </span>",
"      was 11.3 and 25.9 months, respectively. The corresponding values for the 346 patients treated with",
"      <span class=\"nowrap\">",
"       XELOX/bevacizumab",
"      </span>",
"      were 10.8 and 23 months.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       XELOX-1/NO16966",
"      </span>",
"      trial compared XELOX or FOLFOX4 with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/150\">",
"       150",
"      </a>",
"      ]. Median PFS was significantly better in the two bevacizumab-containing groups, although the magnitude of benefit was smaller than expected, and response rates were not significantly higher (",
"      <a class=\"graphic graphic_table graphicRef72526 \" href=\"mobipreview.htm?21/5/21595\">",
"       table 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/150\">",
"       150",
"      </a>",
"      ]. Bevacizumab-treated patients discontinued treatment more often because of toxicity than disease progression; the authors postulated that failure to continue therapy until disease progression offset the benefit of adding bevacizumab.",
"     </li>",
"     <li>",
"      ECOG 3200 randomly assigned 829 patients with previously treated (with 5-FU or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ) mCRC to FOLFOX4,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      alone (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two weeks) or FOLFOX4 plus bevacizumab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/151\">",
"       151",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       bevacizumab/FOLFOX4",
"      </span>",
"      group had a significantly better PFS (7.3 versus 4.7 months) and median overall survival (12.9 versus 10.8 months) compared to FOLFOX4 alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h4\">",
"     Fluoropyrimidines alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    also adds benefit to first-line",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/152-157\">",
"     152-157",
"    </a>",
"    ]. In two randomized phase II trials in which previously untreated patients were assigned to bolus",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    with or without bevacizumab (5 or 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks), response rates were approximately two-fold higher with bevacizumab, and median survival was extended by 7.7 and 3.7 months for the two doses respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/152,153\">",
"     152,153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is active in first-line combination with fluoropyrimidines for mCRC beyond combinations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . For patients in whom either oxaliplatin or irinotecan need to be held because of toxicity, it is reasonable to continue the fluoropyrimidine plus bevacizumab, or even bevacizumab alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H17#H17\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Reducing drug toxicity with chemotherapy holidays'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also appropriate to use",
"    <span class=\"nowrap\">",
"     5-FU/LV",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in patients who are not good candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Second-line bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the increasing use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in first-line regimens, an important clinical issue is whether it should be continued in patients who switch to an alternative regimen after failing first-line bevacizumab-containing therapy. An association between survival and exposure to bevacizumab beyond first progression was suggested in an analysis of the observational BRiTE registry of 1953 patients who progressed after receiving a first-line bevacizumab-containing regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/158\">",
"     158",
"    </a>",
"    ], in a preliminary report from the ARIES observational cohort study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/159\">",
"     159",
"    </a>",
"    ], and from a retrospective analysis of 573 patients treated with and without second-line bevacizumab from community-based US Oncology practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was directly studied in a European trial (the TML study) in which 820 patients with unresectable mCRC progressing within three months of receiving first-line chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    were randomly assigned to fluoropyrimidine-based chemotherapy with or without bevacizumab (2.5",
"    <span class=\"nowrap\">",
"     mg/kg/week)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/161\">",
"     161",
"    </a>",
"    ]. Continuation of bevacizumab with the second line chemotherapy regimen was associated with a significant improvement in progression-free (median 5.7 versus 4.1 months) and overall survival (median 11.2 versus 9.8 months), and bevacizumab-related adverse events were not increased compared with historical data of first-line bevacizumab treatment. Although significantly more patients achieved disease control in the bevacizumab group (68 versus 54 percent), objective response rates in both arms were low (5.4 versus 3.9 percent for bevacizumab and no bevacizumab, respectively).",
"   </p>",
"   <p>",
"    Based upon these results, in January 2013, US FDA approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for use in combination with fluoropyrimidine-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or fluoropyrimidine-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based chemotherapy for treatment of patients with mCRC whose disease has progressed on a first-line bevacizumab-containing regimen. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients treated with a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing chemotherapy regimen, the use of bevacizumab beyond progression in conjunction with a second-line fluoropyrimidine-based chemotherapy regimen can be considered a standard approach. However, for patients with K-ras wild-type tumors who are receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based second line regimens, bevacizumab should not be used in conjunction with an anti-EGFR antibody. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H6688281#H6688281\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Agents targeting the EGFR'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H64\">",
"     'Dual antibody therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    are counterbalanced by its side effect profile, which includes serious and potentially fatal adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/162\">",
"     162",
"    </a>",
"    ]. Potentially serious side effects include proteinuria and the nephrotic syndrome, hypertension, bleeding, GI tract perforation, and arterial and possibly venous thromboembolic events:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intermittent urinalysis is recommended during therapy because of the risk of proteinuria and nephrotic syndrome, although elevated proteinuria only infrequently affects treatment decisions (2 percent of cases in one series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/163\">",
"       163",
"      </a>",
"      ]). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651225341#H1651225341\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Proteinuria/nephrotic syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Guidelines for pretreatment assessment, monitoring, and management of elevated blood pressure in patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      are available (",
"      <a class=\"graphic graphic_table graphicRef73373 graphicRef63338 \" href=\"mobipreview.htm?37/10/38061\">",
"       table 9A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/164\">",
"       164",
"      </a>",
"      ]. This subject is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The risk of major bleeding is approximately 2 to 3 percent. This subject is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227385#H1651227385\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bevacizumab and aflibercept'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      increases the risk of arterial thromboembolic events; whether the risk of venous thromboembolic events is increased is unclear. This subject is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H291526420#H291526420\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Bevacizumab and aflibercept'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other risks are impaired surgical wound healing GI perforation, and fistula formation. Many cases involve perforation of an in situ bowel primary. However, surgical site complications (both perforation and fistula formation) can also occur at previously resected primary sites, often in the setting of prior irradiation or a prior anastomotic leak. Because of this risk, and the long half-line of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (20 days), at least 28 days (preferably six to eight weeks) should elapse between surgery and last dose of bevacizumab, except in emergency situations. This topic is addressed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227429#H1651227429\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Delayed wound healing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227451#H1651227451\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intestinal perforation/fistula formation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other rare side effects include reversible posterior leukoencephalopathy, nasal septum perforation, and jaw osteonecrosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651228672#H1651228672\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Osteonecrosis of the jaw'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651228679#H1651228679\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Reversible posterior leukoencephalopathy and brain capillary leak syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651229346#H1651229346\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Nasal septal perforation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23212877\">",
"    <span class=\"h2\">",
"     Aflibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    (VEGF Trap, Zaltrap&reg;) is a recombinant fusion protein consisting of VEGF binding portions from key domains of human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1. It functions as a decoy receptor that prevents intravascular and extravascular VEGF-A, VEGF-B, and PlGF (placenta growth factor) from binding to their receptors. In cell-free systems, this molecule binds with higher affinity to VEGF-A than does",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/165\">",
"     165",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Aflibercept is approved in the United States for use in combination with FOLFIRI for the treatment of patients with mCRC that is resistant to or has progressed following an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimen. Approval was based on the placebo-controlled VELOUR trial, in which 1226 patients with mCRC that had progressed during or within six months of receiving oxaliplatin-containing chemotherapy with or without bevacizumab were randomly assigned to FOLFIRI with aflibercept (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) or placebo, every two weeks until progression. The aflibercept was administered over one hour prior to FOLFIRI. Median overall survival was significantly longer in patients treated with aflibercept (13.5 versus 12.1 months) as was median PFS (6.9 versus 4.7 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/166\">",
"     166",
"    </a>",
"    ]. Treatment benefit was similar regardless of prior bevacizumab exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/167\">",
"     167",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Grade 3-4 adverse events were reported in 84 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    versus 63 percent of those receiving FOLFIRI alone. Among the grade 3 or 4 toxicities that were more frequent with aflibercept were hypertension (19.3 versus 1.5 percent), proteinuria (7.9 versus 1.2 percent), hemorrhage (2.9 versus 1.7 percent), arterial thromboembolic events (1.8 versus 0.5 percent), and venous thromboembolic events (7.9 versus 6.3 percent). While the side effect profile of aflibercept plus FOLFIRI was consistent with other agents targeting VEGF (bleeding, hypertension, proteinuria, wound infection, arterial thromboembolic events), rates of grade 3 or 4 diarrhea (19.3 versus 7.8 percent), mucositis (13.7 versus 5 percent), complicated neutropenia (5.7 versus 2.8 percent), infection (12.3 versus 6.9 percent), and",
"    <span class=\"nowrap\">",
"     fatigue/asthenia",
"    </span>",
"    (16.9 versus 10.6 percent) associated with aflibercept in this trial were higher than usually seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , as were rates of treatment discontinuation for toxicity (27 versus 12 percent with FOLFIRI alone).",
"   </p>",
"   <p>",
"    Particularly given the data on benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    after progression on a first-line bevacizumab-containing regimen, whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    plus second-line FOLFIRI is the preferred approach after progression on first-line FOLFOX plus bevacizumab is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H56909840#H56909840\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , because of the risk of impaired wound healing, bowel perforation, and fistula formation, at least 28 days should elapse between major surgery and administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , except in emergency situations. This recommendation does not apply to minor procedures such as implantation of a venous access device. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227429#H1651227429\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Delayed wound healing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H687211801#H687211801\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Aflibercept'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56909045\">",
"    <span class=\"h2\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    (BAY 73-4506) is an orally active inhibitor of angiogenic (including the VEGF receptors 1 to 3), stromal, and oncogenic receptor tyrosine kinases. It is structurally similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways.",
"    <br/>",
"    <br/>",
"    Activity in refractory mCRC was shown in the CORRECT trial, in which 760 patients who had progressed after multiple standard therapies were randomly assigned to best supportive care plus regorafenib (160 mg orally once daily for three of every four weeks) or placebo. Patients assigned to regorafenib had a modest though statistically significant improvement in median overall survival (6.4 versus 5 months, hazard ratio 0.77, 95% CI 0.64-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/168\">",
"     168",
"    </a>",
"    ]. The difference in progression-free survival was statistically significant with a hazard ratio of 0.49 (median 1.9 versus 1.7 months). The disease control rate was higher with regorafenib (41 versus 15 percent), but only five patients (1 percent) experienced a partial response (versus one patient, 0.4 percent, receiving placebo). The group receiving regorafenib had more grade 3 or 4 hand-foot skin reaction (17 versus 0.4 percent), fatigue (10 versus 5 percent), hypertension (7 versus 1 percent), diarrhea (7 versus 1 percent) and skin rash (6 versus 0 percent). Fatal hepatic failure occurred in 1.6 percent of patients treated with regorafenib versus 0.4 percent in the placebo group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In October 2012,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    received approval from the US FDA for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based chemotherapy, an anti-VEGF agent, and, if K-ras wild type, an anti-EGFR therapy. In Europe, it is available on single \"named patient\" compassionate access basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     AGENTS TARGETING THE EGFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth factors such as epidermal growth factor (EGF) and its receptor (EGFR) may be involved in autocrine or paracrine control of CRC cell growth, or in the development of angiogenesis or metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/169-171\">",
"     169-171",
"    </a>",
"    ]. Two MoAbs targeting the EGFR are active for treatment of mCRC,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (Erbitux) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    (Vectibix).",
"   </p>",
"   <p>",
"    It is now well-established that biomarker analysis is critical to patient selection for therapy with an EGFR inhibitor. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    are only effective in the subset of patients whose tumors have wild-type (WT) and not mutated K-ras (approximately 40 percent of all mCRCs). A Provisional Clinical Opinion issued by the American Society of Clinical Oncology (ASCO) recommends that all patients being considered for anti-EGFR therapy undergo K-ras mutation testing of their tumors and that treatment with these agents be restricted to those with wild-type K-ras [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/172\">",
"     172",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H21096055#H21096055\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'K-ras'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Whether all mutations in K-ras predict resistance to EGFR-targeted therapies is unclear. Furthermore, WT K-ras does not guarantee benefit; even among patients with WT K-ras tumors, the majority do not respond to therapy with an EGFR inhibitor. Several other biomarkers are under study, all of which require further validation before being incorporated into clinical practice. It is likely that a more comprehensive biomarker analysis will be needed to identify the subgroup of patients who truly benefit from treatment with these agents. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    , a",
"    <span class=\"nowrap\">",
"     mouse/human",
"    </span>",
"    chimeric MoAb, binds to the EGFR of both tumor and normal cells, competitively inhibiting ligand binding, and inducing receptor dimerization and internalization. It is unclear whether these actions represent the mechanism of antitumor action.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h3\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    monotherapy was compared to best supportive care (BSC) in a randomized trial of 572 patients who had failed or were intolerant of all recommended therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/173\">",
"     173",
"    </a>",
"    ]. Median overall survival was significantly better with cetuximab (6.1 versus 4.6 months), as were measures of HR-QOL, including physical function and global health scores.",
"   </p>",
"   <p>",
"    In a subsequent reanalysis, the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    were restricted to patients whose tumors lacked a K-ras mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/174,175\">",
"     174,175",
"    </a>",
"    ]. Among patients with mutated K-ras, there was no significant difference between cetuximab and BSC in terms of overall or PFS, or quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h3\">",
"     Plus irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    might reverse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    resistance was initially suggested in a study of 138 patients with irinotecan-refractory CRC who received irinotecan at the same schedule as previously administered (350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks or 125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for four of every six weeks) plus cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/176\">",
"     176",
"    </a>",
"    ]. The trial was only reported as an abstract, but 15 percent had a partial response, and the median TTP was 6.5 months.",
"   </p>",
"   <p>",
"    Benefit for combined therapy has also been shown in the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EPIC trial randomly assigned 1298",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -refractory patients to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/177\">",
"       177",
"      </a>",
"      ]. PFS was significantly higher with combined therapy (median 4 versus 2.6 months), as were rates of objective response (16 versus 4 percent) and overall disease control (61 versus 46 percent). While median survival was not significantly different (10.7 versus 10 months), one-half of the patients receiving irinotecan alone subsequently received cetuximab after progression, potentially obscuring a survival difference. Despite more skin rash (76 versus 5 percent), grade 3 or 4 diarrhea (28 versus 16 percent), and fatigue (8 versus 3 percent), QOL assessments favored combined therapy.",
"     </li>",
"     <li>",
"      The BOND trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (350",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks, 180",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every two weeks, or 125",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for four of every six weeks) plus weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      versus cetuximab alone in 329 patients with irinotecan-refractory mCRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/178\">",
"       178",
"      </a>",
"      ]. Combined therapy was associated with a significantly better response rate (23 versus 11 percent) and TTP (4.1 versus 1.5 months) but only a trend towards better median survival (8.6 versus 6.9 months).",
"     </li>",
"     <li>",
"      First-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      was explored in the CRYSTAL trial, in which 1198 patients with previously untreated mCRC were randomly assigned to FOLFIRI with or without cetuximab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/179\">",
"       179",
"      </a>",
"      ]. Median PFS was modestly but significantly better with cetuximab (8.9 versus 8 months), as was the overall response rate (47 versus 39 percent), but this did not translate into a significant overall survival benefit. However, in a later report, among patients with WT K-ras, response rates were significantly higher in those who received cetuximab in conjunction with chemotherapy (57 versus 40 percent), as was median PFS and overall survival (median 23.5 versus 20 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/180\">",
"       180",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Perhaps more importantly, patients receiving cetuximab had significantly higher rates of surgery for metastases (7 versus 3.7 percent) and a higher rate of complete (R0) resection with curative intent before disease progression (4.8 versus 1.7 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Choice of regimen'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Adverse effects that were more frequent with cetuximab were grade 3 or 4 diarrhea (16 versus 11 percent), skin toxicity (19.7 versus 0.2 percent), and infusion reactions (2.5 versus zero percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"       \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h3\">",
"     Plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although an early trial suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    also seems to restore sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/181\">",
"     181",
"    </a>",
"    ], the results of randomized trials evaluating the benefit of adding cetuximab to an oxaliplatin-based regimen are mixed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/182-185\">",
"     182-185",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The multicenter European phase II OPUS trial compared weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      plus FOLFOX4 versus FOLFOX 4 alone (",
"      <a class=\"graphic graphic_table graphicRef64504 \" href=\"mobipreview.htm?5/20/5454\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/186\">",
"       186",
"      </a>",
"      ]. Combined therapy was associated with a significantly higher response rate (57 versus 34 percent), and a significant 43 percent prolongation in time to disease progression (hazard ratio 0.57, median 8.3 versus 7.2 months), but only a trend toward improved survival (median 22.8 versus 18.5 months, p = 0.39) when the analysis was restricted to patients with WT K-ras tumors. Inexplicably, the use of cetuximab in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -based therapy appeared to have a detrimental effect in patients with K-ras mutated CRC, a finding that has been observed by others in a trial of FOLFOX with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/187\">",
"       187",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H16555527\">",
"       'Panitumumab combinations'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      As was seen in the CRYSTAL trial, the addition of cetuximab to an oxaliplatin-based regimen in the OPUS trial resulted in an enhanced ability for patients to undergo complete (R0) surgical resection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Choice of regimen'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      A CALGB trial of first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      plus either FOLFIRI or FOLFOX was closed early when data on the benefits of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      became available, with 238 patients accrued to one of four arms (FOLFOX with and without cetuximab, FOLFIRI with and without cetuximab) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/184\">",
"       184",
"      </a>",
"      ]. In a preliminary report, response rates were similar with FOLFOX and FOLFIRI (40 versus 36 percent), and in each case, they were significantly higher with the addition of cetuximab (60 versus 44 percent). Data were not available regarding the impact of adding cetuximab to either regimen on PFS or overall survival. Results from this trial have not yet been published.",
"     </li>",
"     <li>",
"      On the other hand, two other trials show no benefit for adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      to a first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      regimen in patients with K-ras wild-type tumors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      United Kingdom MRC COIN trial, which compared first-line",
"      <span class=\"nowrap\">",
"       FOLFOX/CAPOX",
"      </span>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in 1630 patients with mCRC, failed to show any benefit in either response rate or PFS from the addition of cetuximab in the 729 patients with K-ras-WT tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/188\">",
"       188",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Likewise, the NORDIC VII trial indicated a lack of benefit from the addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      to a bolus",
"      <span class=\"nowrap\">",
"       5-FU/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"        leucovorin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"        oxaliplatin",
"       </a>",
"      </span>",
"      (FLOX) regimen in 571 patients with mCRC, even when the 348 patients with K-ras WT tumors were analyzed separately [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/189\">",
"       189",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimens, the benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen remains uncertain. The reason for this discrepancy is unclear, but it may be related to the schedule of the fluoropyrimidine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/190\">",
"     190",
"    </a>",
"    ]. Additional experience with cetuximab in combination with oxaliplatin plus infusional FU will be forthcoming from the EXPLORE trial (FOLFOX4 with or without cetuximab after progression on irinotecan alone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is useful in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for patients with WT K-ras tumors who are refractory to irinotecan and as a single agent for those who are intolerant of irinotecan-based chemotherapy. The approved dosing regimen is weekly, although at least some data support the safety and efficacy of every other week dosing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H38#H38\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Are cetuximab and panitumumab interchangeable?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     Panitumumab",
"    </a>",
"    (Vectibix) is a fully human MoAb specific for the extracellular domain of EGFR. The benefit of panitumumab monotherapy was initially shown in a multicenter trial in which 463 patients refractory to 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    were randomly assigned to best supportive care (BSC) with or without panitumumab (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every two weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/192\">",
"     192",
"    </a>",
"    ]. The objective response rate with panitumumab was 10 percent, and 27 percent had stable disease; the corresponding rates with BSC alone were 0 and 10 percent. Patients receiving panitumumab were significantly more likely to be alive and progression-free at eight weeks (49 versus 30 percent). The lack of a survival difference was likely due to panitumumab use after crossover in the BSC group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/193\">",
"     193",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a later reanalysis, efficacy was limited to patients whose tumors were WT K-ras (partial response and stable disease in 17 and 34 percent, respectively, versus zero and 12 percent with mutated K-ras) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/194\">",
"     194",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects that were significantly more frequent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    were skin toxicity (90 versus 9 percent in the BSC group), diarrhea (21 versus 11 percent), abdominal pain (23 versus 17 percent), fatigue (24 versus 15 percent), and nausea (22 versus 15 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     Panitumumab",
"    </a>",
"    is approved in the US as a single agent \"last resort\" treatment for K-ras wild-type mCRC, after other drugs have failed. However, efficacy is similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/173,195\">",
"     173,195",
"    </a>",
"    ], and the two drugs might be interchangeable as single agents in this setting. Whether panitumumab is of benefit in patients who are refractory to cetuximab is unclear; this subject is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H8976328#H8976328\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Panitumumab after failure of cetuximab'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16555527\">",
"    <span class=\"h3\">",
"     Panitumumab combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are increasing data supporting the efficacy of first, second, and third-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based regimens in patients with WT K-ras tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/187,196-200\">",
"     187,196-200",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A progression-free survival benefit for adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    to a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen (FOLFOX) was shown in the phase III PRIME trial (median PFS 9.6 versus 8 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/187\">",
"     187",
"    </a>",
"    ]; the overall survival benefit, while potentially clinically meaningful, was not statistically significant (23.9 versus 19.7 months). Survival was impaired in patients with K-ras",
"    <strong>",
"     mutant",
"    </strong>",
"    mCRC who were treated with panitumumab plus FOLFOX, a finding that has been noted in other trials testing the addition of panitumumab (and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ) to oxaliplatin-containing chemotherapy.",
"   </p>",
"   <p>",
"    These results, as well as other data indicating impaired survival and enhanced toxicity when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    was added to chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , led to a change in the FDA-approved manufacturer&rsquo;s product labeling in September 2012 that panitumumab was",
"    <strong>",
"     not",
"    </strong>",
"    <strong>",
"     indicated",
"    </strong>",
"    for use in combination with any form of chemotherapy. However, we disagree with this viewpoint. The use of panitumumab rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in combination with FOLFOX is a reasonable alternative first-line regimen in patients with K-ras wild type tumors. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    also support the use of panitumumab in combination with FOLFOX as an option for first-line therapy in patients with K-ras wild type disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H34#H34\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Panitumumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We avoid combining either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing regimen, an approach that is also supported by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines. (See",
"    <a class=\"local\" href=\"#H64\">",
"     'Dual antibody therapy'",
"    </a>",
"    below.) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9346670\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    are weakness, malaise, an acneiform rash, nausea, electrolyte disorders, and with cetuximab, infusion reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9346815\">",
"    <span class=\"h3\">",
"     Infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions occur in up to 25 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , and rates are highest in some areas of the middle southeastern US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/201\">",
"     201",
"    </a>",
"    ]. Most reactions are severe, and 90 percent occur after the first infusion, most within three hours. Premedication with an H1 receptor antagonist is recommended, and drug infusion should not exceed 5",
"    <span class=\"nowrap\">",
"     mL/minute.",
"    </span>",
"    In addition, benefit from premedication with a glucocorticoid in addition to an antihistamine was shown in a report from the MABEL (Monoclonal Antibody Erbitux in A European Pre-Licensure) registry database of over 1000 patients treated with cetuximab plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/202\">",
"     202",
"    </a>",
"    ]. Rates of any infusion reaction were significantly lower among those pretreated with an antihistamine plus a glucocorticoid as compared to an antihistamine alone (7.1 versus 22 percent) and for grade 3 or 4 reactions (1 versus 4.7 percent).",
"   </p>",
"   <p>",
"    In practice, most patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    are also receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , for which premedication with both a glucocorticoid and antihistamine is recommended. For patients receiving cetuximab alone, pretreatment with an antihistamine alone is acceptable, although the addition of a glucocorticoid is reasonable for those who reside or have resided in high risk locations.",
"   </p>",
"   <p>",
"    For patients who develop a severe reaction despite premedication, and for whom continued use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    is thought to be clinically important, desensitization can be attempted and protocols have been published. Another alternative is a switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of infusion reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    is lower than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (4 percent overall, with 1 percent severe). Given the low rates of infusion reactions, routine premedication is not recommended prior to panitumumab infusion. The lower rate of infusion reactions provides a rationale for choosing panitumumab over cetuximab, particularly in high-risk geographic regions such as the middle southeastern US. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link&amp;anchor=H52#H52\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Panitumumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9346932\">",
"    <span class=\"h3\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all agents that target the EGFR, skin reactions are frequent and may be severe. &nbsp;",
"   </p>",
"   <p>",
"    However, rash severity also correlates with better outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/203-205\">",
"     203-205",
"    </a>",
"    ]. A report from the EVEREST trial suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    dose escalation (by 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks, up to 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) is safe and increases response rates in patients who have no or a mild skin reaction within three weeks of starting therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/206\">",
"     206",
"    </a>",
"    ]. The response rate among patients with &le;grade 1 skin toxicity (",
"    <a class=\"graphic graphic_table graphicRef67786 \" href=\"mobipreview.htm?28/34/29227\">",
"     table 10",
"    </a>",
"    ) who were randomized to dose escalation was 30 versus 16 percent in a concurrently randomized group continuing standard dose therapy, and there was also an improvement in disease control rate (70 versus 58 percent), but no indication of improved overall survival. Thus, the clinical benefit of intrapatient cetuximab dose escalation according to grade of early skin reactions remains uncertain.",
"   </p>",
"   <p>",
"    Grading of the severity of the acneiform eruption that is most typical of this class of agents, management of cutaneous toxicity, as well as the use of prophylactic systemic antibiotics, is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=see_link\">",
"     \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9346939\">",
"    <span class=\"h3\">",
"     Electrolyte disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    cause a magnesium-wasting syndrome, which in one report affected 22 percent of 154 patients treated with cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/207,208\">",
"     207,208",
"    </a>",
"    ]. In addition, hypokalemia is also reported (incidence 8 percent in a meta-analysis of patients treated with cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/209\">",
"     209",
"    </a>",
"    ]). Hypomagnesemia may lead to secondary hypocalcemia. Serum levels of magnesium, potassium, and calcium should be monitored periodically during and for at least eight weeks following therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link&amp;anchor=H5#H5\">",
"     \"Signs and symptoms of magnesium depletion\", section on 'Hypocalcemia and hypoparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9346946\">",
"    <span class=\"h3\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis concluded that the use of monoclonal antibodies targeting the EGFR was associated with a statistically significant increase in the risk of venous thromboembolism (VTE) (RR 1.34, 95% CI 1.07-1.68), but not arterial thromboembolism (RR 1.38, 95% CI 0.76-2.51) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/210\">",
"     210",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link&amp;anchor=H19999147#H19999147\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\", section on 'Epidermal growth factor receptor inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The orally active small molecule EGFR inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    are inactive by themselves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/211,212\">",
"     211,212",
"    </a>",
"    ]. Favorable results have been reported in phase II trials of erlotinib with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in previously treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/213\">",
"     213",
"    </a>",
"    ] and with gefitinib plus FOLFOX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/214,215\">",
"     214,215",
"    </a>",
"    ]. To know whether these results are better than with oxaliplatin-based therapy alone will require randomized trials.",
"   </p>",
"   <p>",
"    A preliminary report suggests promise for dual targeting of the EGFR using a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/216\">",
"     216",
"    </a>",
"    ], but randomized trials will be needed to ascertain whether this represents an advance over cetuximab alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h1\">",
"     DUAL ANTIBODY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of simultaneously targeting both VEGF and the EGFR has been addressed in three trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The BOND-2 randomized phase II trial compared",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"        cetuximab",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"        bevacizumab",
"       </a>",
"      </span>",
"      with (CBI) and without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      (CB) in 76 patients with irinotecan- and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      -refractory but bevacizumab-naive mCRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/217\">",
"       217",
"      </a>",
"      ]. Response rates (37 versus 20 percent), TTP (7.3 versus 4.9 months) and overall survival (15.4 versus 11.4 months) all favored CBI. These outcomes with CBI were unprecedented in the salvage setting, and were much less impressive in a subsequent phase II study of this regimen (9 percent response rate, TTP 3.9 months, median survival 10.6 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/218\">",
"       218",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The PACCE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       Panitumumab",
"      </a>",
"      Advanced Colorectal Cancer Evaluation) trial tested the addition of panitumumab to standard first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      (n = 823) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based therapy (n = 230) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/219\">",
"       219",
"      </a>",
"      ]. Panitumumab treatment was stopped after a preplanned interim analysis detected a significantly inferior PFS in the",
"      <span class=\"nowrap\">",
"       panitumumab/oxaliplatin",
"      </span>",
"      group; median overall survival was also lower (19.4 versus 24.5 months).",
"     </li>",
"     <li>",
"      The CAIRO2 trial studied first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      plus XELOX with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/220\">",
"       220",
"      </a>",
"      ]. PFS was significantly worse with dual antibody therapy. Even patients with wild-type K-ras tumors did not benefit from the addition of cetuximab. (See",
"      <a class=\"local\" href=\"#H51\">",
"       'Agents targeting the EGFR'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that dual antibody therapy is not appropriate, at least in the first-line setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H40#H40\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Dual antibody therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h1\">",
"     COMBINATION VERSUS SEQUENTIAL SINGLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line therapy with combinations of fluoropyrimidines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has markedly improved response rates, PFS and survival compared to fluoropyrimidines alone. However, survival is positively impacted by subsequent therapy, and upfront combination therapy also increases toxicity and cost.",
"   </p>",
"   <p>",
"    The question of whether patients should receive initial combination therapy or fluoropyrimidine monotherapy has been addressed in two randomized trials, neither of which showed that survival was adversely impacted by initial single agent therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/221,222\">",
"     221,222",
"    </a>",
"    ]. However, the median survival for all groups in both trials (which ranged from 13.9 to 17.4 months) was lower than expected for modern chemotherapy.",
"   </p>",
"   <p>",
"    One possible reason is the low number of patients who eventually received all three active drugs in both trials. The proportion of patients receiving all three active agents correlates strongly with median survival in all large published phase III trials over the last decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/32/44554/abstract/97\">",
"     97",
"    </a>",
"    ]. Furthermore, neither trial used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    either as first-line or salvage therapy. These agents improve PFS, and bevacizumab also improves overall survival when used in the first-line regimen (see",
"    <a class=\"local\" href=\"#H44\">",
"     'Agents targeting VEGF'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Thus, the available evidence continues to support initial combination chemotherapy for most patients, particularly for those whose metastases might be potentially resectable after an initial chemotherapy response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These trial results and the implications for clinical practice are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H5#H5\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Initial doublet combinations versus sequential single agent chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients with metastatic colorectal cancer (mCRC) cannot be cured, although a subset with liver",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lung-isolated disease are potentially curable with surgery. For other patients, treatment is palliative and generally consists of systemic chemotherapy.",
"     </li>",
"     <li>",
"      For decades, 5-fluorouracil (FU) was the sole active agent. This has changed markedly since the year 2000, with the approval of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      , three humanized monoclonal antibodies that target vascular endothelial growth factor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ) and the epidermal growth factor receptor (EGFR,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      ), and most recently, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      , a fully-humanized recombinant fusion protein consisting of vascular endothelial growth factor (VEGF) binding portions from the human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      , an orally active inhibitor of angiogenic tyrosine kinases (including the VEGF receptors 1 to 3), and other membrane and intracellular kinases. The best way to combine and sequence these agents is still not established. Benefit from monoclonal antibodies targeting the EGFR is restricted to patients whose tumors do not contain mutated K-ras. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H6688281#H6688281\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Agents targeting the EGFR'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic chemotherapy produces meaningful improvements in median survival and progression-free survival. These benefits are most pronounced with regimens containing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      in combination with FU. The median overall survival for patients with unresectable mCRC who receive best supportive care (BSC) alone is approximately five to six months. Although no trial has compared these regimens to BSC alone, median survival now approaches two years. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=see_link&amp;anchor=H183911606#H183911606\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: General principles\", section on 'Chemotherapy versus supportive care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The available evidence supports initial combination chemotherapy for most patients, particularly for those whose metastases might be potentially resectable after an initial chemotherapy response. However, the best way to combine and sequence these agents is not established, nor is the optimal duration of treatment. In general, patients benefit more from access to all active agents than from a particular treatment sequence of specific regimens used as individual \"lines\" of therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H6#H6\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Clinical trials'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/1\">",
"      Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997; 15:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/2\">",
"      van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G&gt;A mutation causing DPD deficiency. Clin Cancer Res 2001; 7:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/3\">",
"      O'Dwyer PJ, Manola J, Valone FH, et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 2001; 19:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/4\">",
"      Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/5\">",
"      Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16:3537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/6\">",
"      Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/7\">",
"      Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/8\">",
"      Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/9\">",
"      Kovoor PA, Karim SM, Marshall JL. Is levoleucovorin an alternative to racemic leucovorin? A literature review. Clin Colorectal Cancer 2009; 8:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/10\">",
"      Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/11\">",
"      J&auml;ger E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996; 14:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/12\">",
"      Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/13\">",
"      Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/14\">",
"      Wang WS, Lin JK, Chiou TJ, et al. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer. Hepatogastroenterology 2000; 47:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/15\">",
"      Saltz LB. Another study of how to give fluorouracil? J Clin Oncol 2003; 21:3711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/16\">",
"      de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/17\">",
"      L&eacute;vi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/18\">",
"      Lincoln DW 2nd, Hrushesky WJ, Wood PA. Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer 2000; 88:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/19\">",
"      Cur&eacute; H, Chevalier V, Adenis A, et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/20\">",
"      Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/21\">",
"      Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/22\">",
"      Sch&uuml;ller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/23\">",
"      Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/24\">",
"      Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/25\">",
"      Hoff PM, Pazdur R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004; 22:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/26\">",
"      Lee JJ, Kim TM, Yu SJ, et al. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Jpn J Clin Oncol 2004; 34:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/27\">",
"      Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/28\">",
"      Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005; 23:3104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/29\">",
"      Hennig IM, Naik JD, Brown S, et al. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. J Clin Oncol 2008; 26:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/30\">",
"      Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 1998; 16:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/31\">",
"      Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/32\">",
"      Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/33\">",
"      Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51:5579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/34\">",
"      Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/35\">",
"      Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. \"Tomudex\" Colorectal Cancer Study Group. Ann Oncol 1996; 7:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/36\">",
"      Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/37\">",
"      Cortinovis D, Bajetta E, Di Bartolomeo M, et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer. Tumori 2004; 90:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/38\">",
"      Comella P, Casaretti R, Crucitta E, et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer 2002; 86:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/39\">",
"      Laudani A, Gebbia V, Leonardi V, et al. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res 2004; 24:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/40\">",
"      Aparicio J, Vicent JM, Maestu I, et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 2003; 14:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/41\">",
"      Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008; 6 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/42\">",
"      Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/43\">",
"      Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/44\">",
"      Cunningham D, Pyrh&ouml;nen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/45\">",
"      Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009; 27:2848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/46\">",
"      Michael M, Hedley D, Oza A, et al. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer 2002; 2:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/47\">",
"      Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/48\">",
"      Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/49\">",
"      Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/50\">",
"      K&ouml;hne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23:4856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/51\">",
"      Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/52\">",
"      Delaunoit T, Goldberg RM, Sargent DJ, et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004; 101:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/53\">",
"      Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19:3801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/54\">",
"      Van Cutsem E, Douillard JY, K&ouml;hne CH. Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 2001; 345:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/55\">",
"      Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/56\">",
"      Falcone A, Di Paolo A, Masi G, et al. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001; 19:3456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/57\">",
"      Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for \"Can't Predict Toxicity\"? J Clin Oncol 2002; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/58\">",
"      Mathijssen RH, Verweij J, de Jonge MJ, et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/59\">",
"      Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/60\">",
"      Miya T, Goya T, Fujii H, et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001; 19:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/61\">",
"      Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/62\">",
"      Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9:3246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/63\">",
"      Michael M, Thompson M, Hicks RJ, et al. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol 2006; 24:4228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/64\">",
"      Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/65\">",
"      Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/66\">",
"      Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/67\">",
"      McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/68\">",
"      Carlini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/69\">",
"      Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:3061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/70\">",
"      C&ocirc;t&eacute; JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13:3269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/71\">",
"      Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/72\">",
"      Palomaki GE, Bradley LA, Douglas MP, et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/73\">",
"      Stewart CF, Panetta JC, O'Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007; 25:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/74\">",
"      Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/75\">",
"      Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 2010; 46:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/76\">",
"      Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 2010; 16:3832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/77\">",
"      Deeken JF, Slack R, Marshall JL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer 2008; 113:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/78\">",
"      Shulman K, Cohen I, Barnett-Griness O, et al. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer 2011; 117:3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/79\">",
"      O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006; 24:4534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/80\">",
"      Innocenti F, Vokes EE, Ratain MJ. Irinogenetics: what is the right star? J Clin Oncol 2006; 24:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/81\">",
"      Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/82\">",
"      Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/83\">",
"      Haaz MC, Rivory L, Rich&eacute; C, et al. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998; 58:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/84\">",
"      van der Bol JM, Mathijssen RH, Creemers GJ, et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 2010; 16:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/85\">",
"      van der Bol JM, Mathijssen RH, Loos WJ, et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007; 25:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/86\">",
"      Corona G, Vaccher E, Sandron S, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 2008; 83:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/87\">",
"      Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008; 34:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/88\">",
"      Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009; 115:3858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/89\">",
"      Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/90\">",
"      Borner MM, Bernhard J, Dietrich D, et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005; 16:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/91\">",
"      Patt YZ, Lee FC, Liebmann JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 2007; 30:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/92\">",
"      Souglakos J, Ziras N, Kakolyris S, et al. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Br J Cancer 2012; 106:453.",
"     </a>",
"    </li>",
"    <li>",
"     Aust D, Kohne C, Goekkurt E, et al. Preliminary pharmacogenetic evaluation of toxicity data in the prospective multicentre EORTC trial 40015 in metastatic colorectal cancer (CRC) (abstract). J Clin Oncol 2006; 24:138s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/94\">",
"      Tournigand C, Andr&eacute; T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/95\">",
"      Recchia F, Saggio G, Nuzzo A, et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer 2004; 91:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/96\">",
"      Bidard FC, Tournigand C, Andr&eacute; T, et al. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 2009; 20:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/97\">",
"      Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/98\">",
"      Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/99\">",
"      Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/100\">",
"      deBraud F, Munzone E, Nol&egrave; F, et al. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol 1998; 21:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/101\">",
"      Armand JP, Boige V, Raymond E, et al. Oxaliplatin in colorectal cancer: an overview. Semin Oncol 2000; 27:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/102\">",
"      B&eacute;couarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/103\">",
"      Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/104\">",
"      de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/105\">",
"      Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin in advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 2002; 21:129a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/106\">",
"      Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/107\">",
"      Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/108\">",
"      Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011; 12:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/109\">",
"      Ashley AC, Sargent DJ, Alberts SR, et al. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 2007; 110:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/110\">",
"      S&oslash;rbye H, Glimelius B, Berglund A, et al. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/111\">",
"      Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/112\">",
"      Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/113\">",
"      Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/114\">",
"      Zeuli M, Nardoni C, Pino MS, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003; 14:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/115\">",
"      Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004; 100:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/116\">",
"      Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/117\">",
"      Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005; 104:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/118\">",
"      Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25:4217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/119\">",
"      D&iacute;az-Rubio E, Tabernero J, G&oacute;mez-Espa&ntilde;a A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25:4224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/120\">",
"      Cassidy J, Clarke S, D&iacute;az-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/121\">",
"      Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011; 128:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/122\">",
"      Arkenau HT, Arnold D, Cassidy J, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26:5910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/123\">",
"      Hong YS, Park YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 2012; 13:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/124\">",
"      Rothenberg ML, Oza AM, Burger B, et al. Final results of a phase III trial of 5-FU/Leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU and leucovorin (abstract). Proc Am Soc Clin Oncol 2003; 22:252a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/125\">",
"      Kemeny N, Garay CA, Gurtler J, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004; 22:4753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/126\">",
"      Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/127\">",
"      Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 2003; 21:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/128\">",
"      Maindrault-Goebel F, de Gramont A, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000; 11:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/129\">",
"      Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/130\">",
"      Caussanel JP, L&eacute;vi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/131\">",
"      Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/132\">",
"      Qvortrup C, Jensen BV, Fokstuen T, et al. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Ann Oncol 2010; 21:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/133\">",
"      B&eacute;couarn Y, Gamelin E, Coudert B, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19:4195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/134\">",
"      Stathopoulos GP, Rigatos SK, Stathopoulos JG, et al. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Am J Clin Oncol 2005; 28:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/135\">",
"      Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/136\">",
"      Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21:3761.",
"     </a>",
"    </li>",
"    <li>",
"     Schalhorn A, Ludwig F, Quietzsch D, et al. Phase III Trial of Irinotecan Plus Oxalipatin (IROX) Versus Irinotecan Plus 5-FU/Folinic Acid (FOLFIRI) as First-Line Treatment of Metastatic Colorectal Cancer (CRC): The FIRE-Trial (abstract). J Clin Oncol 2005; 23:250s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/138\">",
"      Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/139\">",
"      Hoff PM, Wolff RA, Xiong H, et al. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer 2006; 106:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/140\">",
"      Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26:5721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/141\">",
"      Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011; 103:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/142\">",
"      Fischer von Weikersthal L, Schalhorn A, Stauch M, et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011; 47:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/143\">",
"      Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249:420.",
"     </a>",
"    </li>",
"    <li>",
"     Masi G, Loupakis F, Baldi G, et al. First-line irinotecan, oxaliplatin and infusional 5-FU/leucovorin (FOLFOXIRI) in combination with bevacizumab in metastastic colorectal cancer patients: a phase II study by the GONO group (abstract). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 26, 2008.",
"    </li>",
"    <li>",
"     Loupakis F, Cremolini C, Masi G, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC). Results of the phase III randomized TRIBE trial (abstract). Data presented at the 2013 ASCO Gastrointesitnal Cancers Symposium, San ?Francisco, CA, January 24-26, 2013. Abstract availabe online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=133&amp;abstractID=105744 (Accessed on February 14, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/146\">",
"      Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/147\">",
"      Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/148\">",
"      Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/149\">",
"      Stathopoulos GP, Batziou C, Trafalis D, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/150\">",
"      Saltz LB, Clarke S, D&iacute;az-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/151\">",
"      Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/152\">",
"      Vincenzi B, Santini D, Russo A, et al. Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 2009; 115:4849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/153\">",
"      Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23:3697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/154\">",
"      Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/155\">",
"      Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/156\">",
"      Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24:3354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/157\">",
"      Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28:3191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/158\">",
"      Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26:5326.",
"     </a>",
"    </li>",
"    <li>",
"     Bekaii-Saab TS, Grothey A, Bendell JC, et al. Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study (abstract). J clin oncol 2012; 30 (suppl 4): abstract 535. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=88734 (Accessed on March 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/160\">",
"      Cartwright TH, Yim YM, Yu E, et al. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer 2012; 11:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/161\">",
"      Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/162\">",
"      Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/163\">",
"      Yeh J, Frieze D, Martins R, Carr L. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother 2010; 44:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/164\">",
"      Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/165\">",
"      Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/166\">",
"      Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499.",
"     </a>",
"    </li>",
"    <li>",
"     Allegra CJ, Lakomy R, Tabernero J, et al. Effects of prior bevacizumab (B) use on outcomes from the VELOUS study: A phase III study of aflibercept (Afl) and FOLFIRI in patients with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. J Clin Oncol 30, 2012 (suppl; abstr 3505). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=98446 (Accessed on June 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/168\">",
"      Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/169\">",
"      Kawamoto K, Onodera H, Kan S, et al. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 1999; 85:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/170\">",
"      Messa C, Russo F, Caruso MG, Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/171\">",
"      el-Hariry I, Pignatelli M, Lemoine N. Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours. J Pathol 1997; 181:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/172\">",
"      Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/173\">",
"      Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/174\">",
"      Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/175\">",
"      Au HJ, Karapetis CS, O'Callaghan CJ, et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 2009; 27:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/176\">",
"      Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-225) plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor (abstract). Proc Am Soc Clin Oncol 2001; 20:3a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/177\">",
"      Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/178\">",
"      Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/179\">",
"      Van Cutsem E, K&ouml;hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/180\">",
"      Van Cutsem E, K&ouml;hne CH, L&aacute;ng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/181\">",
"      Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007; 18:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/182\">",
"      Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/183\">",
"      Tabernero J, Van Cutsem E, D&iacute;az-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25:5225.",
"     </a>",
"    </li>",
"    <li>",
"     Venook A, Niedzwicki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) &plusmn; cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results (abstract). J Clin Oncol 2006; 24:148s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/185\">",
"      Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/186\">",
"      Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/187\">",
"      Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/188\">",
"      Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/189\">",
"      Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/190\">",
"      Ku GY, Haaland BA, de Lima Lopes G Jr. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol 2012; 70:231.",
"     </a>",
"    </li>",
"    <li>",
"     Jennis A, Polikoff J, Mitchell E, et al. Erbitux (Cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial (abstract). J Clin Oncol 2005; 23:264s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/192\">",
"      Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/193\">",
"      Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008; 19:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/194\">",
"      Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/195\">",
"      Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/196\">",
"      Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/197\">",
"      Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/198\">",
"      K&ouml;hne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2012; 138:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/199\">",
"      Cohn AL, Shumaker GC, Khandelwal P, et al. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2011; 10:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/200\">",
"      Andr&eacute; T, Blons H, Mabro M, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013; 24:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/201\">",
"      O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/202\">",
"      Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26:5335.",
"     </a>",
"    </li>",
"    <li>",
"     Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer aith no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetics and efficacy data of a randomized study (abstract). Data presented at the 4th annual ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 20, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/204\">",
"      Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009; 115:1544.",
"     </a>",
"    </li>",
"    <li>",
"     Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): pooled analysis of five clinical trials (abstract). J Clin Oncol 2007; 25:196s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/206\">",
"      Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30:2861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/207\">",
"      Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/208\">",
"      Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/209\">",
"      Cao Y, Liu L, Liao C, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol 2010; 66:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/210\">",
"      Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012; 23:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/211\">",
"      Townsley CA, Major P, Siu LL, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006; 94:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/212\">",
"      Rothenberg ML, LaFleur B, Levy DE, et al. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005; 23:9265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/213\">",
"      Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 24:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/214\">",
"      Kuo T, Cho CD, Halsey J, et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:5613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/215\">",
"      Zampino MG, Magni E, Massacesi C, et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 2007; 110:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/216\">",
"      Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol 2012; 30:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/217\">",
"      Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557.",
"     </a>",
"    </li>",
"    <li>",
"     Segal NH, Reidy-Lagunes D, Capanu M, et al. Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer patients who have progressed on a bavacizumab containing regimen (the BOND 2.5 study) (Abstract # 4087). J Clin Oncol 2009; 27:189s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/219\">",
"      Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/220\">",
"      Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/221\">",
"      Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/32/44554/abstract/222\">",
"      Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370:143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2470 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44554=[""].join("\n");
var outline_f43_32_44554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H66\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FLUOROPYRIMIDINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Leucovorin plus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Optimizing the schedule and dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chronomodulated 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Orally active fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - UFT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Raltitrexed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IRINOTECAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Irinotecan alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Irinotecan plus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Drug sequence and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pharmacokinetic variability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - UGT1A1 polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Irinotecan plus capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Irinotecan after oxaliplatin failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OXALIPLATIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Oxaliplatin alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      First-line oxaliplatin plus 5-FU/LV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Oxaliplatin/FU/LV versus FU/LV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Oxaliplatin/FU/LV versus irinotecan/FU/LV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Capecitabine plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - First-line XELOX versus FOLFOX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5025419\">",
"      S-1 plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Oxaliplatin after irinotecan failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Neurotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Chronomodulated schedules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      OXALIPLATIN PLUS IRINOTECAN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Second-line IROX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      First-line IROX or FOLFOXIRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      AGENTS TARGETING VEGF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23212813\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H516273937\">",
"      - First-line use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Irinotecan regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Oxaliplatin regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Fluoropyrimidines alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Second-line bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23212877\">",
"      Aflibercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56909045\">",
"      Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      AGENTS TARGETING THE EGFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      - Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      - Plus irinotecan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      - Plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Panitumumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16555527\">",
"      - Panitumumab combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9346670\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9346815\">",
"      - Infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9346932\">",
"      - Rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9346939\">",
"      - Electrolyte disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9346946\">",
"      - Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      DUAL ANTIBODY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      COMBINATION VERSUS SEQUENTIAL SINGLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2470\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2470|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/20/5454\" title=\"table 1\">",
"      Chemo regimens met CRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/17/37149\" title=\"table 2\">",
"      Modified de Gramont schedule for gastrointestinal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/2/19502\" title=\"table 3\">",
"      FOLFIRI regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 4\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/53/9053\" title=\"table 5\">",
"      TREE trials met colorectal ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/60/14286\" title=\"table 6\">",
"      XELOX regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/32/3599\" title=\"table 7\">",
"      FOLFOXIRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/5/21595\" title=\"table 8\">",
"      Results Roche trial NO16966",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/7/22652\" title=\"table 9A\">",
"      HTN with VEGF inhib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/36/33356\" title=\"table 9B\">",
"      Risk factors BP VSP rx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/34/29227\" title=\"table 10\">",
"      NCI CTCAE acneiform rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=related_link\">",
"      Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21833?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10963?source=related_link\">",
"      Treatment protocols for colorectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_32_44555="Microbiology of IAI";
var content_f43_32_44555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Organisms isolated in the amniotic fluid of 404 patients with intraamniotic infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group B streptococcus",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        14.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escherichia coli",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterococci",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gardnerella vaginalis",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        24.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptostreptococcus sp.",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        9.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteroids bivius",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        29.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteroides fragilis",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fusobacterium sp.",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any gram-negative anaerobe",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        38.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma hominis",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        30.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ureaplasma urealyticum",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        47.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Sperling, RS, Newton, E, Gibbs, RS. J Infect Dis 1988; 157:113.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44555=[""].join("\n");
var outline_f43_32_44555=null;
var title_f43_32_44556="Measurement of BP";
var content_f43_32_44556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the measurement of blood pressure to diagnose and treat hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Posture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Initially, check for postural changes by taking readings after five minutes supine, then immediately and two minutes after standing; this is particularly important in patients over age 65 years, diabetics, or those taking antihypertensive drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sitting pressures are recommended for routine follow-up; the patient should sit quietly with the back supported for five minutes and the arm supported at the level of the heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Circumstances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No caffeine during the hour preceding the reading, and no smoking during the preceding 30 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No exogenous adrenergic stimulants, such as phenylephrine in decongestants or eye drops for pupillary dilatation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A quiet, warm setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Home readings should be taken upon varying circumstances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cuff size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The length of the bladder should be 80 percent, and the width of the bladder should be at least 40 percent of the circumference of the upper arm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Manometer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aneroid gauges should be calibrated every six months against a mercury manometer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Number of readings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Take at least two readings on each visit, separated by as much time as possible; if readings vary by more than 5 mmHg, take additional reading until two consecutive readings are close",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For the diagnosis of hypertension, take three readings at least one week apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Initially, take blood pressure in both arms; if pressures differ, use the higher arm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If the arm pressure is elevated, take the pressure in one leg, particularly in patients under age 30 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflate the bladder quickly to 20 mmHg above the systolic pressure as estimated from loss of radial pulse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deflate the bladder 3 mmHg per second",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Record the Korotkoff phase V (disappearance) as the diastolic pressure except in children in whom use of phase IV (muffling) may be preferable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If the Korotkoff sounds are weak, have the patient raise the arm, open and close the hand five to ten times, and then inflate the bladder quickly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recordings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Note the pressure, patient position, arm, and cuff size: eg, 140/90, seated, right arm, large adult cuff",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44556=[""].join("\n");
var outline_f43_32_44556=null;
var title_f43_32_44557="Barretts esophagus Endosc";
var content_f43_32_44557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus: endoscopic appearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy shows long segments of columnar epithelium extending well above the esophagogastric junction. This is the characteristic endoscopic appearance of Barrett's esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stuart J Spechler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44557=[""].join("\n");
var outline_f43_32_44557=null;
var title_f43_32_44558="Liver metastases on somatostatin receptor scintigraphy";
var content_f43_32_44558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver metastases demonstrating high-grade radiotracer uptake on somatostatin receptor scintigraphy fused with SPECT/CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SPECT: single photon emission computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44558=[""].join("\n");
var outline_f43_32_44558=null;
var title_f43_32_44559="Echocardiogram apical 4-chamber showing right heart enlargement";
var content_f43_32_44559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram apical 4-chamber showing severe right atrial and right ventricular enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical&nbsp;four chamber view shows severe enlargement of the right ventricle (RV) and right atrium (RA) with evidence of high right sided filling pressures. The interventricular septum (red arrow) and the interatrial septum (white arrows) bulge into the left ventricle (LV) and left atrium (LA) respectively. While this finding is nonspecific for any one specific etiology of increased right sided pressure and volume overload, it is typical of patients with right ventricular infarction resulting in low output state. Also seen is a pericardial effusion (PE).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_32_44559=[""].join("\n");
var outline_f43_32_44559=null;
